Pyrrolidine compounds

ABSTRACT

The present application relates to compounds of formula 
     
       
         
         
             
             
         
       
     
     wherein R 1 , R 2 , R 3 , R 4 , and n are defined herein
 
or to a pharmaceutically active salt thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson&#39;s disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

PRIORITY TO RELATED APPLICATION(S)

This application claims the benefit of European Patent Application No.09179797.7, filed Dec. 18, 2009, which is hereby incorporated byreference in its entirety.

BACKGROUND OF THE INVENTION

The three main mammalian tachykinins, substance P(SP), neurokinin A(NKA) and neurokinin B (NKB) belong to the family of neuropeptidessharing the common COOH-terminal pentapeptide sequence ofPhe-X-Gly-Leu-Met-NH₂. As neurotransmitters, these peptides exert theirbiological activity via three distinct neurokinin (NK) receptors termedas NK-1, NK-2 and NK-3. SP binds preferentially to the NK-1 receptor,NKA to the NK-2 and NKB to the NK-3 receptor.

The NK-3 receptor is characterized by a predominant expression in CNSand its involvement in the modulation of the central monoaminergicsystem has been shown. These properties make the NK-3 receptor apotential target for central nervous system disorders such as anxiety,depression, bipolar disorders, Parkinson's disease, schizophrenia andpain (Neurosci. Letters, 2000, 283, 185-188; Exp. Opin. Ther. Patents2000, 10, 939-960; Neuroscience, 1996, 74, 403-414; Neuropeptides, 1998,32, 481-488).

Schizophrenia is one of the major neuropsychiatric disorders,characterized by severe and chronic mental impairment. This devastatingdisease affects about 1% of the world's population. Symptoms begin inearly adulthood and are followed by a period of interpersonal and socialdysfunction. Schizophrenia manifests as auditory and visualhallucinations, paranoia, delusions (positive symptoms), blunted affect,depression, anhedonia, poverty of speech, memory and attention deficitsas well as social withdrawal (negative symptoms).

For decades scientists and clinicians have made efforts with the aim ofdiscovering an ideal agent for the pharmacological treatment ofschizophrenia. However, the complexity of the disorders, due to a widearray of symptoms, has hampered those efforts. There are no specificfocal characteristics for the diagnosis of schizophrenia and no singlesymptom is consistently present in all patients. Consequently, thediagnosis of schizophrenia as a single disorder or as a variety ofdifferent disorders has been discussed but not yet resolved. The majordifficulty in the development of a new drug for schizophrenia is thelack of knowledge about the cause and nature of this disease. Someneurochemical hypotheses have been proposed on the basis ofpharmacological studies to rationalize the development of acorresponding therapy: the dopamine, the serotonin and the glutamatehypotheses. But taking into account the complexity of schizophrenia, anappropriate multireceptor affinity profile might be required forefficacy against positive and negative signs and symptoms. Furthermore,an ideal drug against schizophrenia would preferably have a low dosageallowing once-per-day dosage, due to the low adherence of schizophrenicpatients.

In recent years clinical studies with selective NK1 and NK2 receptorantagonists appeared in the literature showing results for the treatmentof emesis, depression, anxiety, pain and migraine (NK1) and asthma (NK2and NK1). The most exciting data were produced in the treatment ofchemotherapy-induced emesis, nausea and depression with NK1 and inasthma with NK2-receptor antagonists. In contrast, no clinical data onNK3 receptor antagonists have appeared in the literature until 2000.Osanetant (SR 142,801) from Sanofi-Synthelabo was the first identifiedpotent and selective non-peptide antagonist described for the NK3tachykinin receptor for the potential treatment of schizophrenia, whichwas reported in the literature (Current Opinion in InvestigationalDrugs, 2001, 2(7), 950-956 and Psychiatric Disorders Study 4,Schizophrenia, June 2003, Decision Recources, Inc., Waltham, Mass.). Theproposed drug SR 142,801 has been shown in a phase II trial as active onpositive symptoms of schizophrenia, such as altered behaviour, delusion,hallucinations, extreme emotions, excited motor activity and incoherentspeech, but inactive in the treatment of negative symptoms, which aredepression, anhedonia, social isolation or memory and attentiondeficits.

The neurokinin-3 receptor antagonists have been described as useful inpain or inflammation, as well as in schizophrenia, Exp. Opinion. Ther.Patents (2000), 10(6), 939-960 and Current Opinion in InvestigationalDrugs, 2001, 2(7), 950-956 956 and Psychiatric Disorders Study 4,Schizophrenia, June 2003, Decision Recources, Inc., Waltham, Mass.).

SUMMARY OF THE INVENTION

The present application provides compounds of formula

wherein

-   R¹ is hydrogen, halogen, cyano, lower alkyl or lower alkyl    substituted by halogen;-   n is 1, 2 or 3, wherein when n is 2 or 3, each R¹ is the same or    different;-   R² is C₂₋₇-alkyl or C₃₋₆-cycloalkyl;-   R³ is the group

wherein

-   X is CH or N;-   R⁵ is hydrogen, —C(O)-lower alkyl, —C(O)O-lower alkyl, S(O)₂-lower    alkyl, —C(O)CH₂O-lower alkyl, —C(O)—CH₂—CN, or is    -   —C(O)-cycloalkyl, cycloalkyl, or —CH₂-cycloalkyl,    -   wherein the cycloalkyl groups are optionally substituted by        lower alkyl, —CH₂—O-lower alkyl, lower alkoxy, CF₃, halogen or        cyano, or is    -   —C(O)-heterocycloalkyl, heterocycloalkyl, —C(O)-heteroaryl,        heteroaryl, —C(O)-aryl or aryl,    -   which heterocycloalkyl, heteroaryl or aryl groups are optionally        substituted by halogen, lower alkyl, ═O, lower alkoxy, lower        alkyl substituted by halogen, lower alkyl substituted by        hydroxy, —C(O)—CH₂—N(di-lower alkyl), C(O)NH-lower alkyl,        C(O)NH₂, —O—C(O)-lower alkyl, C(O)-lower alkyl, S(O)₂-lower        alkyl or cyano;-   R⁴ is aryl, which is optionally substituted by halogen, hydroxy,    lower alkyl, lower alkyl substituted by halogen, S(O)₂-lower alkyl,    cyano or lower alkoxy;    or to a pharmaceutically active salt thereof.

The invention includes all stereoisomeric forms, including individualdiastereoisomers and enantiomers of the compound of formula (I) as wellas racemic and non-racemic mixtures thereof.

The present invention provides novel compounds of formula I, theirmanufacture, pharmaceutical compositions containing them and methods forproducing such compositions.

The present compounds are high potential NK-3 receptor antagonists forthe treatment of depression, pain, bipolar disorders, psychosis,Parkinson's disease, schizophrenia, anxiety and attention deficithyperactivity disorder (ADHD).

The preferred indications using the compounds of the present inventionare depression, psychosis, Parkinson's disease, schizophrenia, anxietyand attention deficit hyperactivity disorder (ADHD).

DETAILED DESCRIPTION OF THE INVENTION

The following definitions of the general terms used in the presentdescription apply irrespective of whether the terms in question appearalone or in combination.

As used herein, the terms “lower alkyl” and “C₂₋₇-alkyl” denote astraight- or branched-chain hydrocarbon group containing from 2-7 carbonatoms, for example, ethyl, propyl, isopropyl, n-butyl, i-butyl, t-butyland the like. Preferred lower alkyl groups are groups with 2-4 carbonatoms.

As used herein, the term “lower alkoxy” denotes a lower alkyl group asdefined above which is connected with an oxygen atom.

The term “lower alkyl substituted by halogen” denotes a lower alkylgroup as defined above, wherein at least one hydrogen atom is replacedby halogen, for example —CF₃, —CHF₂, —CH₂F, —CH₂CF₃, —C(CH₃)₂CF₃,—CH(CH₃)CH₂CF₃, —CH(CH₃)CF₃, —CH₂CH₂CF₃, —CH₂CH₂CH₂CF₃, —CH₂CH₂CF₂CF₃,—CH₂CH₂CH₂CF₂CF₃, —CH₂CF₂CF₃ and the like. Preferred lower alkylsubstituted by halogen groups are groups having 1-5 carbon atoms.

The term “halogen” denotes chlorine, iodine, fluorine and bromine.

The term “lower alkyl substituted by hydroxy” denotes a lower alkylgroup as defined above, wherein at least one hydrogen atom is replacedby a hydroxyl group.

The term “cycloalkyl” denotes a saturated carbon ring containing from3-6 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl,cyclohexyl, cycloheptyl, and the like.

The term “aryl” denotes a cyclic aromatic hydrocarbon radical consistingof one or more fused rings containing 6-14 carbon atoms in which atleast one ring is aromatic in nature, for example phenyl, naphthyl,1,2,3,4-tetrahydronaphthalenyl or indanyl. Preferred is the phenylgroup.

The term “heteroaryl” denotes a cyclic aromatic radical consisting ofone or more fused rings containing 5-14 ring atoms, preferablycontaining 5-10 ring atoms, in which at least one ring is aromatic innature, and which contains at least one heteroatom, selected from N, Oand S, for example quinoxalinyl, dihydroisoquinolinyl, pyrazinyl,pyrazolyl, 2,4-dihydro-pyrazol-3-one, pyridinyl, isoxazolyl,benzo[1,3]dioxol, [1.3.4]thiadiazol, pyridazinyl, pyrimidinyl,benzotriazol-5-yl, benzoimidazol-5-yl, [1,3,4]-oxadiazol-2-yl,[1,2,4]triazol-1-yl, [1,6]naphthyridin-2-yl,imidazo[4,5-b]pyridine-6-yl, tetrazolyl, thiazolyl, thiadiazolyl,thienyl, furyl, imidazol-1-yl, or benzofuranyl. Preferred heteroarylgroup is pyridine-2, 3 or 4-yl.

The term “heterocycloalkyl” denotes a cyclic nonaromatic ring,containing one or two heteroatoms selected from N, S and O, for examplethe following groups: tetrahydropyranyl,1,1-dioxo-hexahydro-1λ⁶-thiopyranyl,1,1-dioxo-tetrahydro-1λ⁶-thiophenyl, oxetanyl, morpholinyl,[1,4]diazepam-1-yl, piperazinyl, pyrrolidinyl, piperidinyl,tetrahydrofuranyl, tetrahydrothiophenyl, piperidin-4-yl or1,1-dioxo-λ⁶-thiomorpholinyl.

“Pharmaceutically acceptable,” such as pharmaceutically acceptablecarrier, excipient, etc., means pharmacologically acceptable andsubstantially non-toxic to the subject to which the particular compoundis administered.

The term “pharmaceutically acceptable acid addition salts” embracessalts with inorganic and organic acids, such as hydrochloric acid,nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid,fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid,methanesulfonic acid, p-toluenesulfonic acid and the like.

“Therapeutically effective amount” means an amount that is effective toprevent, alleviate or ameliorate symptoms of disease or prolong thesurvival of the subject being treated.

One embodiment of the invention provides compounds of formula Ia

wherein

-   R¹ is halogen;-   n is 1, 2 or 3, wherein when n is 2 or 3, each halogen is the same    or different;-   R² is C₂₋₇-alkyl or C₃₋₆-cycloalkyl;-   R³ is the group

wherein

-   R⁵ is hydrogen, —C(O)-lower alkyl, —C(O)O-lower alkyl, S(O)₂-lower    alkyl, —C(O)—CH₂—CN, or is —C(O)-cycloalkyl,    -   wherein the cycloalkyl groups are optionally substituted by        lower alkyl, —CH₂—O-lower alkyl, lower alkoxy, CF₃, halogen or        cyano, or is    -   —C(O)-heterocycloalkyl, —C(O)-heteroaryl, heteroaryl,        —C(O)-aryl,    -   which heterocycloalkyl, heteroaryl or aryl groups are optionally        substituted by halogen, lower alkyl, ═O, lower alkyl substituted        by halogen, lower alkyl substituted by hydroxy,        —C(O)—CH₂—N(di-lower alkyl), C(O)NH₂, —O—C(O)-lower alkyl,        C(O)-lower alkyl, S(O)₂-lower alkyl or cyano;-   R⁴ is aryl, which is optionally substituted by halogen,    or a pharmaceutically active salt thereof.

A preferred aryl group is phenyl.

The following compounds are encompassed by the present invention:

-   rac-{(3S,4R)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   rac-{(3S,4R)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-isopropyl-carbamic    acid 4-fluoro-phenyl ester;-   rac-{(3S,4R)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-isobutyl-carbamic    acid 4-fluoro-phenyl ester;-   rac-{(3S,4R)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-cyclopropyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3R,4S)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3R,4S)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3R,4S)-4-(4-Chloro-phenyl)-1-(4′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3R,4S)-4-(4-Chloro-phenyl)-1-(5′-methanesulfonyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrazin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(6-cyano-pyridazin-3-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(4-Chloro-phenyl)-1-(4′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-methanesulfonyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrazin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(6-cyano-pyridazin-3-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3R,4S)-4-(4-Chloro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3R,4S)-4-(4-Chloro-phenyl)-1-(5′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-isopropyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-isopropyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-isopropyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(6-cyano-pyridazin-3-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-isopropyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrazin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-isopropyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3R,4S)-4-(4-Chloro-phenyl)-1-(5′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-isopropyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-cyclopropyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-cyclopropyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-cyclopropyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(6-cyano-pyridazin-3-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-cyclopropyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrazin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-cyclopropyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3R,4S)-4-(4-Chloro-phenyl)-1-(5′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-cyclopropyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(5′-Chloro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   Ethyl-[(3S,4R)-4-(4-fluoro-phenyl)-1-(5′-methanesulfonyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   4-{(3R,4S)-3-(4-Chloro-3-fluoro-phenyl)-4-[ethyl-(4-fluoro-phenoxycarbonyl)-amino]-pyrrolidine-1-carbonyl}-piperidine-1-carboxylic    acid tert-butyl ester;-   [(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(5′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(5′-chloro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(6′-cyano-3,4,5,6-tetrahydro-2H-[1,3′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(4′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(5′-fluoro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(5′-methyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(5′-Chloro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(3,4-Difluoro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(6′-Cyano-3,4,5,6-tetrahydro-2H-[1,3′]bipyridinyl-4-carbonyl)-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(3,4-Difluoro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(4′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(3,4-Difluoro-phenyl)-1-(5′-fluoro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(3,4-Difluoro-phenyl)-1-(5′-methyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(6-cyano-pyridazin-3-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-[1-(6-Cyano-pyridazin-3-yl)-piperidine-4-carbonyl]-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(5-cyano-pyrazin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-[1-(5-Cyano-pyrazin-2-yl)-piperidine-4-carbonyl]-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(5′-methanesulfonyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(3,4-Difluoro-phenyl)-1-(5′-methanesulfonyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(3-methyl-oxetane-3-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(3,3-difluoro-cyclobutanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(1-cyclobutanecarbonyl-piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(1-trifluoromethyl-cyclobutanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(3-fluoro-cyclobutanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(2,2-difluoro-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(1-trifluoromethyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(1-cyano-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(2,2-dimethyl-tetrahydro-pyran-4-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(5-trifluoromethyl-pyridine-2-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(5-fluoro-pyridine-2-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(4-cyano-benzoyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(4-fluoro-benzoyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(5-trifluoromethyl-pyrazine-2-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(6-cyano-pyridine-3-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(1-Acetyl-piperidine-4-carbonyl)-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(1-methanesulfonyl-piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(1-Acetyl-piperidine-4-carbonyl)-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[5′-(1-hydroxy-1-methyl-ethyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(3-methyl-oxetane-3-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 2-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(1-cyano-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 2-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(5-trifluoromethyl-pyridine-2-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 2-fluoro-phenyl ester;-   [(3S,4R)-4-(4-Chloro-phenyl)-1-(1-cyclobutanecarbonyl-piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(3-methyl-oxetane-3-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(3-fluoro-cyclobutanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(3,3-difluoro-cyclobutanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(3-methoxy-cyclobutanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(1-trifluoromethyl-cyclobutanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(2-cyano-acetyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(1-cyano-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(1-trifluoromethyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(2,2-difluoro-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(tetrahydro-pyran-4-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(2,2-dimethyl-tetrahydro-pyran-4-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(1-methoxymethyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(2,2-dimethyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(5-trifluoromethyl-pyridine-2-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(5-fluoro-pyridine-2-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(6-oxo-piperidine-3-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(1-isopropyl-6-oxo-piperidine-3-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(1-isopropyl-6-oxo-piperidine-3-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(3,4-Difluoro-phenyl)-1-[1-((S)-4-oxo-azetidine-2-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(3,4-Difluoro-phenyl)-1-[1-(6-oxo-piperidine-3-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[5′-(1-hydroxy-ethyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(5′-Carbamoyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-chloro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(5′-Carbamoyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(3,4-Dichloro-phenyl)-1-(5′-fluoro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(5′-Chloro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(3,4-Dichloro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(5′-Carbamoyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(3-Chloro-4-fluoro-phenyl)-1-(5′-fluoro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(3-Chloro-4-fluoro-phenyl)-1-(5′-chloro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(3-Chloro-4-fluoro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(3-chloro-4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-((S)-4-oxo-azetidine-2-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-[5′-(2-Diethylamino-acetyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl]-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester; and-   acetic acid    4-{(3R,4S)-3-(4-chloro-phenyl)-4-[ethyl-(4-fluoro-phenoxycarbonyl)-amino]-pyrrolidine-1-carbonyl}-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl    ester.

In one embodiment the invention provides the following compounds

-   rac-{(3S,4R)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(4-Chloro-phenyl)-1-(4′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-methanesulfonyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrazin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(6-cyano-pyridazin-3-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   Ethyl-[(3S,4R)-4-(4-fluoro-phenyl)-1-(5′-methanesulfonyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   4-{(3R,4S)-3-(4-Chloro-3-fluoro-phenyl)-4-[ethyl-(4-fluoro-phenoxycarbonyl)-amino]-pyrrolidine-1-carbonyl}-piperidine-1-carboxylic    acid tert-butyl ester;-   [(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(4′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(5′-fluoro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(5′-methyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(5′-Chloro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(3,4-Difluoro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(6′-Cyano-3,4,5,6-tetrahydro-2H-[1,3′]bipyridinyl-4-carbonyl)-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(3,4-Difluoro-phenyl)-1-(5′-fluoro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(3,4-Difluoro-phenyl)-1-(5′-methyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-[1-(6-Cyano-pyridazin-3-yl)-piperidine-4-carbonyl]-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-[1-(5-Cyano-pyrazin-2-yl)-piperidine-4-carbonyl]-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(3,4-Difluoro-phenyl)-1-(5′-methanesulfonyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(3-methyl-oxetane-3-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(3,3-difluoro-cyclobutanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(1-cyclobutanecarbonyl-piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(1-trifluoromethyl-cyclobutanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(3-fluoro-cyclobutanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(2,2-difluoro-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(1-trifluoromethyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(1-cyano-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(2,2-dimethyl-tetrahydro-pyran-4-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(5-fluoro-pyridine-2-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(4-fluoro-benzoyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(5-trifluoromethyl-pyrazine-2-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(6-cyano-pyridine-3-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(1-Acetyl-piperidine-4-carbonyl)-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(1-Acetyl-piperidine-4-carbonyl)-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[5′-(1-hydroxy-1-methyl-ethyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(4-Chloro-phenyl)-1-(1-cyclobutanecarbonyl-piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(3-methyl-oxetane-3-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(3-fluoro-cyclobutanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(3,3-difluoro-cyclobutanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(3-methoxy-cyclobutanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(1-trifluoromethyl-cyclobutanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(2-cyano-acetyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(1-cyano-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(1-trifluoromethyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(2,2-difluoro-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(tetrahydro-pyran-4-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(2,2-dimethyl-tetrahydro-pyran-4-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(1-methoxymethyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(2,2-dimethyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(5-fluoro-pyridine-2-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   {(3S,4R)-4-(4-Chloro-phenyl)-1-[5′-(1-hydroxy-ethyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(5′-Carbamoyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-chloro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(5′-Carbamoyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(3,4-Dichloro-phenyl)-1-(5′-fluoro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(5′-Chloro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(3,4-Dichloro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(5′-Carbamoyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(3-Chloro-4-fluoro-phenyl)-1-(5′-fluoro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(3-Chloro-4-fluoro-phenyl)-1-(5′-chloro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-4-(3-Chloro-4-fluoro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester;-   [(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(3-chloro-4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic    acid 4-fluoro-phenyl ester; and-   Acetic acid    4-{(3R,4S)-3-(4-chloro-phenyl)-4-[ethyl-(4-fluoro-phenoxycarbonyl)-amino]-pyrrolidine-1-carbonyl}-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-yl    ester.

An embodiment of the invention provides compounds of formula

whereinR¹ is hydrogen, halogen, cyano, lower alkyl or lower alkyl substitutedby halogen;n is 1, 2 or 3, wherein when n is 2 or 3, each R¹ is the same ordifferent;R² is C₂₋₇-alkyl or C₃₋₆-cycloalkyl;R³ is a non aromatic heterocyclic group

wherein

X is CH; Y is —N(R⁷)—;

R⁶ is hydrogen;o and m are each independently 0, 1 or 2;p is 0 or 1;R^(7′) is hydrogen, —C(O)-lower alkyl, —C(O)O-lower alkyl, S(O)₂-loweralkyl, —C(O)CH₂O-lower alkyl, or iscycloalkyl, —CH₂-cycloalkyl or —C(O)-cycloalkyl,wherein the cycloalkyl groups are optionally substituted by lower alkyl,CF₃, halogen or cyano, or is—C(O)-heterocycloalkyl, heterocycloalkyl, heteroaryl, —C(O)-heteroaryl,—C(O)-aryl, or aryl,which heterocycloalkyl, heteroaryl or aryl groups are optionallysubstituted by halogen, lower alkyl, lower alkoxy, lower alkylsubstituted by halogen, C(O)NH-lower alkyl, C(O)NH₂, C(O)-lower alkyl,S(O)₂-lower alkyl or cyano;

Z is —O—;

R⁴ is (CH₂)_(q)-aryl or is (CH₂)_(q)-heteroaryl, which aryl orheteroaryl rings are optionally substituted by halogen, hydroxy, loweralkyl, lower alkyl substituted by halogen, S(O)₂-lower alkyl, cyano orby lower alkoxy;q is 0 or 1;or to a pharmaceutically active salt thereof.

The present compounds of formula I and their pharmaceutically acceptablesalts can be prepared by processes described below, which processcomprises

a) coupling a compound of formula II

with a suitable carbamoyl chloride, acid chloride or carboxylic acid toafford a compound of formula I

wherein the substituents R¹, R², R³ and R⁴ are as defined aboveand if desired, converting the compounds obtained into pharmaceuticallyacceptable acid addition salts;orb) coupling a compound with formula III

with a corresponding chloroformate, acid anhydride or a mixture oftriphosgene and corresponding alcohol or amine to afford a compound offormula I

wherein the substituents R¹, R², R³ and R⁴ are as defined aboveand if desired, converting the compounds obtained into pharmaceuticallyacceptable acid addition salts.

The following schemes 1 and 2 describe the processes for the preparationof compounds of formula I in more detail. The starting material offormula II is a known compound and can be prepared according to methodsknown in the art.

According to scheme 1, the 3,4-disubstituted pyrrolidine VI is preparedvia a stereo specific 1,3-dipolar cycloaddition between the2-nitrostyrene compound IV and the azomethine ylide generated in situfrom theN-(methoxymethyl)-N-(phenylmethyl)-N-(trimethylsilyl)methylamine V inthe presence of a catalytic amount of acid, such as TFA. Reduction ofthe nitro moiety of VI using standard conditions for example SnCl₂.H₂Oyields VII. The amino moiety of VII is subsequently alkylated to produceVIII. Reaction of VIII with an acid anhydride, chloroformate or amixture of triphosgene and an alcohol or amine in the presence of a baseaffords IX. Selective N-debenzylation is then carried out using severalknown procedures which are compatible with the substitution patterns ofthe aromatic rings to afford II. Finally, compounds I are prepared via acoupling with a suitable carbamoyl chloride, acid chloride or carboxylicacide. Alternatively, pyrrolidine II is coupled with the correspondingacid to afford a compound of formula IA which can be deprotected toafford the piperidine of formula IB which might be further derivatisedto obtain final compounds of formula I.

According to scheme 2, the secondary amine of the intermediates VII canbe protected, for instance with a Boc group to afford a compound offormula X, followed by a selective debenzylation to produce XI. Then acoupling with a suitable carbamoyl chloride, acid chloride or carboxylicacid gives XII. Deprotection with TFA affords the free amine XIII, whichafter reaction with an acid anhydride, chloroformate or a mixture oftriphosgene and an alcohol or amine in the presence of a base affordscompounds of formula I.

Example 1rac-{(3S,4R)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

a) rac-(3R,4S)-1-Benzyl-3-(3,4-dichloro-phenyl)-4-nitro-pyrrolidine

A solution ofN-(methoxymethyl)-N-(phenylmethyl)-N-(trimethylsilyl)methylamine (32.50g, 0.135 mol) in CH₂Cl₂ (70 mL) was added drop wise, over a 30 minutesperiod, to a stirred solution of1,2-dichloro-4-((E)-2-nitro-vinyl)-benzene (19.60 g, 0.09 mol) andtrifluoroacetic acid (1.54 mL, 0.013 mol) in CH₂Cl₂ (160 mL) at 0° C.The ice bath was removed, and the solution was stirred at 25° C. for anadditional 48 h. It was then concentrated and purification by flashchromatography (SiO₂, EtOAc/H 1:6) afforded 25.0 g (79%) of the titlecompound as a yellow oil. MS m/e: 351.0 (M+H⁺).

b) rac-(3S,4R)-1-Benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-ylamine

To a stirred solution ofrac-(3R,4S)-1-benzyl-3-(3,4-dichloro-phenyl)-4-nitro-pyrrolidine (11.60g, 33.0 mmol) in EtOAc (200 mL) was added in one portion SnCl₂.2H₂O(37.26 g, 0.165 mol). The reaction mixture was then heated at reflux for4 hours, cooled down to ambient temperature and a saturated aqueoussolution of NaHCO₃ was added. The salts were filtered off and theproduct extracted with EtOAc. The organic phases were then dried overNa₂SO₄, and concentration under vacuum gave 5.7 g (54%) ofrac-(3S,4R)-1-benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-ylamine as ayellow oil. The product was then used in the next step without furtherpurification. ES-MS m/e: 321.2 (M+H⁺).

c)rac-(3S,4R)-[1-Benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-carbamicacid tert-butyl ester

To a solution ofrac-(3S,4R)-1-benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-ylamine (30.64g, 0.095 mol) in dichloromethane (300 mL) was added N,N-diisopropylamine(32.65 mL, 0.191 mol) and 4-dimethylaminopyridine (1.17 g, 0.01 mol).The reaction mixture was cooled to 0° C. and di-tert-butyl-dicarbonate(24.98 g, 0.114 mol) was added. After stirring for 2 h at 0° C. and atambient temperature for 18 h it was concentrated. Purification by flashchromatography (SiO₂, EtOAc/Heptane 1:3) afforded 5.82 g (14%) of thetitle compound as a light yellow solid. ES-MS m/e: 421.1 (M+H⁺).

d) rac-(3S,4R)-[4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-carbamic acidtert-butyl ester

To a solution ofrac-(3S,4R)-[1-benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-carbamicacid tert-butyl ester (5.59 g, 0.013 mol) and N,N-diisopropylamine (6.81mL, 0.017 mol) in toluene (60 mL) was added at ambient temperature1-chloroethyl formate (1.88 mL, 0.017 mol) and the reaction mixture wasstirred for 24 h. It was concentrated and the resulting residue wasdiluted in methanol (60 mL) and stirred for 3 h at ambient temperature.Concentration afforded the crude title compound (6.59 g, 67% purity) asa light brown solid which was directly used without furtherpurification.

e)rac-(3S,4R)-{4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-carbamicacid tert-butyl ester

To a solution of1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carboxylic acid (4.48 g,0.02 mol) in DMF (40 ml) was addedO-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate (9.54 g, 0.03 mol). After stirring for 10 min atambient temperature N,N-diisopropyl ethyl amine (19.82 ml, 0.116 mol)and a solution ofrac-(3S,4R)-[4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-carbamic acidtert-butyl ester (6.39 g, 67% purity, 0.013 mol) in DMF (45 ml) wereadded and the reaction mixture was stirred for 19 h at this temperature.It was diluted with ethyl acetate (80 mL) and the organic layer waswashed with water (80 mL), aqueous sodium carbonate (1M, 40 mL) andbrine (40 mL). The aqueous layers were extracted with ethyl acetate (160mL). the combined organic layers were dried over sodium sulfate andconcentrated. Purification by flash chromatography (SiO₂, EtOAc/methanol100:0 to 80:20) afforded 5.84 g (87%) of the title compound as a lightbrown foam. ES-MS m/e: 524.1 (M+H⁺).

f)rac-(3S,4R)-[3-Amino-4-(3,4-dichloro-phenyl)-pyrrolidin-1-yl]-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-yl]-methanone

To a solution ofrac-(3S,4R)-{4-(3,4-dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-carbamicacid tert-butyl ester (5.747 g, 0.011 mol) in dichloromethane (55 mL)was added trifluoroacetic acid (8.39 mL, 0.110 mol) and the reactionmixture was stirred for 4 h at ambient temperature. The reaction mixturewas basified by addition of aqueous sodium carbonate (1M, 10 mL). Theorganic layers were washed with water (8 mL) and the aqueous layers wereextracted with dichloromethane (10 mL). The combined org. layers weredried over sodium sulfate and concentration afforded 4.30 g (92%) of thetitle compound as a light brown foam. ES-MS m/e: 524.2 (M+H⁺).

g)rac-[(3R,4S)-3-(3,4-Dichloro-phenyl)-4-ethylamino-pyrrolidin-1-yl]-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-yl]-methanone

To a solution ofrac-(3S,4R)-[3-Amino-4-(3,4-dichloro-phenyl)-pyrrolidin-1-yl]-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-yl]-methanone(50 mg, 0.12 mmol) in ethanol (0.3 mL) were added acetaldehyde (10 uL,0.18 mmol) and sodiumcyanoborohydride (15 mg, 0.24 mmol) and thereaction mixture was stirred at ambient temperature for 3 h. It wasconcentrated and the residue separated between water and ethylacetate.The organic layer was dried over sodium sulfate and concentrated.Purification by chromatography (SiO₂, dichloromethane:methanol=100:0 to95:5) afforded the title compound (30 mg, 56%) as a light yellow oil. MSm/e: 452.3 [M]⁺.

h)rac-{(3S,4R)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

To a solution ofrac-[(3R,4S)-3-(3,4-dichloro-phenyl)-4-ethylamino-pyrrolidin-1-yl]-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-yl]-methanone(25 mg, 0.06 mmol) in dichloromethane (1 mL) was addedN,N-diisopropylethylamine (10 uL, 0.06 mmol). It was cooled to 0° C. and4-fluorophenyl chloroformate (8 uL, 0.06 mmol) was added and thereaction mixture was stirred for 30 min at this temperature and then 2 hat ambient temperature. Concentration and purification by chromatography(SiO₂, ethyl acetate) afforded the title compound (17 mg, 52%) as acolorless foam. MS m/e: 590.4 [M]⁺.

Example 2rac-{(3S,4R)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-isopropyl-carbamicacid 4-fluoro-phenyl ester

a)rac-[(3R,4S)-3-(3,4-Dichloro-phenyl)-4-isopropylamino-pyrrolidin-1-yl]-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-yl]-methanone

To a solution ofrac-(3S,4R)-[3-Amino-4-(3,4-dichloro-phenyl)-pyrrolidin-1-yl]-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-yl]-methanone(120 mg, 0.28 mmol) in dichloromethane (1 mL) were added acetone (21 uL,0.28 mmol) and sodiumtriacetoxy-borohydride (72 mg, 0.34 mmol) andacetic acid (16 uL, 0.28 mmol) and the reaction mixture was stirred atambient temperature for 3 h. It was diluted with dichloromethane andwashed with aqueous sodiumhydrogenecarbonate (1M). The organic layer wasdried over sodium sulfate and concentrated affording the title compound(95 mg, 72%) as a light yellow foam. MS m/e: 466.3 [M]⁺.

b)rac-{(3S,4R)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-isopropyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of example 1(step h), the title compoundrac-{(3S,4R)-4-(3,4-dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-isopropyl-carbamicacid 4-fluoro-phenyl ester was prepared fromrac-[(3R,4S)-3-(3,4-Dichloro-phenyl)-4-isopropylamino-pyrrolidin-1-yl]-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-yl]-methanoneinstead ofrac-{4-[(3S,4R)-3-(3,4-dichloro-phenyl)-4-methylamino-pyrrolidine-1-carbonyl]-piperidin-1-yl}-(1-methyl-cyclopropyl)-methanoneusing 4-fluorophenyl chloroformate and was obtained as a colorless foam.MS m/e: 604.3 [M]⁺.

Example 3rac-{(3S,4R)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-isobutyl-carbamicacid 4-fluoro-phenyl ester

a)rac-[(3R,4S)-3-(3,4-Dichloro-phenyl)-4-isobutylamino-pyrrolidin-1-yl]-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-yl]-methanone

To a solution ofrac-(3S,4R)-[3-Amino-4-(3,4-dichloro-phenyl)-pyrrolidin-1-yl]-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-yl]-methanone(150 mg, 0.35 mmol) in dichloromethane (1 mL) were addedisobutylaldehyde (39 uL, 0.42 mmol) and sodiumcyanoborohydride (27 mg,0.42 mmol) and acetic acid (51 uL, 0.88 mmol) and the reaction mixturewas stirred at ambient temperature for 3 h. It was diluted withdichloromethane and washed with aqueous sodiumhydrogenecarbonate (1M).The organic layer was dried over sodium sulfate and concentratedaffording the title compound (140 mg, 82%) as a light yellow oil. MSm/e: 480.3 [M]⁺.

b)rac-{(3S,4R)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-isobutyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of example 1(step h), the title compoundrac-{(3S,4R)-4-(3,4-dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-isobutyl-carbamicacid 4-fluoro-phenyl ester was prepared fromrac-[(3R,4S)-3-(3,4-Dichloro-phenyl)-4-isobutylamino-pyrrolidin-1-yl]-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-yl]-methanoneinstead ofrac-{4-[(3S,4R)-3-(3,4-dichloro-phenyl)-4-methylamino-pyrrolidine-1-carbonyl]-piperidin-1-yl}-(1-methyl-cyclopropyl)-methanoneusing 4-fluorophenyl chloroformate and was obtained as a colorless foam.MS m/e: 618.5 [M]⁺.

Example 4rac-{(3S,4R)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-cyclopropyl-carbamicacid 4-fluoro-phenyl ester

a)rac-[(3R,4S)-3-(3,4-Dichloro-phenyl)-4-cyclopropylamino-pyrrolidin-1-yl]-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-yl]-methanone

To a solution ofrac-(3S,4R)-[3-Amino-4-(3,4-dichloro-phenyl)-pyrrolidin-1-yl]-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-yl]-methanone(150 mg, 0.35 mmol) in dichloromethane (1 mL) were added((1-ethoxycyclopropyl)oxy)trimethylsilan (62 uL, 0.35 mmol) andsodiumtrisacetoxyborohydride (90 mg, 0.42 mmol) and acetic acid (20 uL,0.35 mmol) and the reaction mixture was stirred at ambient temperaturefor 20 h. It was diluted with dichloromethane and washed with aqueoussodiumhydrogenecarbonate (1M). The organic layer was dried over sodiumsulfate and concentrated. Purification by chromatography (SiO₂,dichloromethane:methanol=100:0 to 95:5) afforded the title compound (30mg, 18%) as a light yellow oil. MS m/e: 464.3 [M]⁺.

b)rac-{(3S,4R)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-cyclopropyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of example 1(step h), the title compoundrac-{(3S,4R)-4-(3,4-dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-cyclopropyl-carbamicacid 4-fluoro-phenyl ester was prepared fromrac-[(3R,4S)-3-(3,4-Dichloro-phenyl)-4-cyclopropylamino-pyrrolidin-1-yl]-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-yl]-methanoneinstead ofrac-{4-[(3S,4R)-3-(3,4-dichloro-phenyl)-4-methylamino-pyrrolidine-1-carbonyl]-piperidin-1-yl}-(1-methyl-cyclopropyl)-methanoneusing 4-fluorophenyl chloroformate and was obtained as a colorless foam.MS m/e: 602.3 [M]⁺.

Example 5{(3S,4R)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

Example 6

{(3R,4S)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

rac-{(3S,4R)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester was subjected to column chromatography onchiral phase to yield{(3S,4R)-4-(3,4-dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester (MS (m/e): 590.3 [M]⁺) as a colorless foam{(3R,4S)-4-(3,4-dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester (MS (m/e): 590.3 [M]⁺) as a colorless foam.

Example 7{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

a) rac-(3R,4S)-1-benzyl-3-(4-chloro-phenyl)-4-nitro-pyrrolidine

In analogy to the procedure described for the synthesis ofrac-(3R,4S)-1-Benzyl-3-(3,4-dichloro-phenyl)-4-nitro-pyrrolidine(example 1, step a) the title compound was prepared from(E)-1-chloro-4-(2-nitrovinyl)benzene andN-(methoxymethyl)-N-(phenylmethyl)-N-(trimethylsilyl)methylamine aslight yellow viscous oil. MS m/e: 317.1 [M+H]⁺.

b) rac-(3S,4R)-1-benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-ylamine

In anaolgy to the procedure descrive for the synthesis ofrac-(3S,4R)-1-Benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-ylamine(example 1, step b) the title compound was prepared fromrac-(3R,4S)-1-benzyl-3-(4-chloro-phenyl)-4-nitro-pyrrolidine throughreduction with SnCl₂ as brown oil. MS m/e: 287.1 [M+H]⁺.

c)rac-[(3S,4R)-1-Benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-her

A mixture of 2.14 g (7.09 mmol)rac-(3S,4R)-1-benzyl-4-(4-chlorophenyl)-pyrrolidin-3-amine, 540 uL (9.5mmol) acetaldehyde, 609 uL (10.6 mmol) acetic acid and 2.25 g (10.6mmol) sodium triacetoxyborohydride was stirred at 20° C. over night.Water and Na₂CO₃ aq. was added and the mixture was extracted with ethylacetate. The combined organic layers were dried with Na₂SO₄ andevaporated to dryness. the residue was taken up in 60 mL DCM. 1.15 gDIPEA (8.86 mmol) and 43.3 mg DMAP (354 μmol) was added. The brownishsolution was cooled with an ice-bath. A solution of 1.48 g (8.51 mmol)4-fluorophenyl chloroformate in 15 mL DCM was added drop-wise and themixture was stirred at 0-5° C. for 1 h. Na₂CO₃ aq. was added and themixture was extracted with DCM. The combined organic layers were washedwith brine, dried with Na₂SO₄ and evaporated to dryness. The residue waspurified by flash column chromatography on silica eluting with agradient formed from TBDME and heptane to yield after evaporation of theproduct containing fractions 1.62 g (50%) of the title compound asyellow oil. MS m/e: 453.3 [M+H]⁺.

d)rac-4-{(3R,4S)-3-(4-Chloro-phenyl)-4-[ethyl-(4-fluoro-phenoxycarbonyl)-amino]-pyrrolidine-1-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester

A mixture of 1.62 g (3.58 mmol) rac-4-fluorophenyl(3S,4R)-1-benzyl-4-(4-chlorophenyl)pyrrolidin-3-yl(ethyl)carbamate and624 mg (4.83 mmol) DIPEA in 25 mL toluene was cooled to 0-5° C. 690 mg(4.83 mmol) 1-chloroethyl chloroformate was added and the mixture wasstirred over night at ambient temperature and evaported to dryness. Theresidue was dried under high vacuum at 60-70° C. to yieldrac-[(3S,4R)-4-(4-Chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic acid4-fluoro-phenyl ester. The residue was dissolved in 25 mL methanol,stirred for 90 min and evaporated to dryness. The residue was taken upin 25 mL DMF and 2.5 g (19.3 mmol) DIPEA was added. A solution of 738 mg(3.22 mmol) 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid and 1.35g (3.54 mmol) HATU in 25 mL DMF was added and the mixture was stirredfor 30 min at room temperature and evaporated under high vacuum. Theresidue was dissolved in ethyl acetate and washed with 10% aq.Na₂CO₃ andbrine. The aqueous layers were extracted with ethyl acetate and thecombined organic layers were dried over Na₂SO₄, filtered off andconcentrated under vacuum. The residue was purified by columnchromatography over silica eluting with a gradient formed from ethylacetate and heptane to yield after evaporation of the product containingfractions 1.8 g (97%) of the title compound as light brown foam. MS m/e:574.2 [M+H]⁺.

e)4-{(3R,4S)-3-(4-Chloro-phenyl)-4-[ethyl-(4-fluoro-phenoxycarbonyl)-amino]-pyrrolidine-1-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester

rac-4-{(3R,4S)-3-(4-Chloro-phenyl)-4-[ethyl-(4-fluoro-phenoxycarbonyl)-amino]-pyrrolidine-1-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester was subjected to separation by chiral HPLC elutingwith i-propanol/heptane. After evaporation of the product containingfractions the title compound was obtained as yellow viscous oil. MS m/e:474.3 [M-Boc]⁺. And

4-{(3S,4R)-3-(4-Chloro-phenyl)-4-[ethyl-(4-fluoro-phenoxycarbonyl)-amino]-pyrrolidine-1-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester

rac-4-{(3R,4S)-3-(4-Chloro-phenyl)-4-[ethyl-(4-fluoro-phenoxycarbonyl)-amino]-pyrrolidine-1-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester was subjected to separation by chiral HPLC elutingwith i-propanol/heptane. After evaporation of the product containingfractions the title compound was obtained as yellow viscous oil. MS m/e:474.3 [M-Boc]⁺.

f)[(3R,4S)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

A mixture of 804 mg (1.4 mmol)4-{(3S,4R)-3-(4-Chloro-phenyl)-4-[ethyl-(4-fluoro-phenoxycarbonyl)-amino]-pyrrolidine-1-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester and 1.6 g (14 mmol) TFA in 25 mL DCM was stirredfor 5 h at room temperature. Water and 2N NaOH aq. was added and themixture was extracted with DCM. The combined organic layers were driedover Na₂SO₄, filtered off and evaporated to yield 577 mg (87%) of thetitle compound as yellow foam. MS m/e: 474.3 [M+H]⁺.

g){(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

A mixture of 94.7 mg (0.2 mmol)[(3R,4S)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester, 83.7 mg (0.3 mmol)2-chloropyrimidine-5-carbonitrile and 129 mg (1 mmol) DIPEA in 2.5 mLDMF was shaken a for 22 h at 65° C. The mixture was subjected topreparative HPLC purification on reversed phase eluting with a gradientformed from acetonitrile, water and NEt₃. The product containingfraction were evaporated to access 58 mg (51%) of the title compound asoff-white solid. MS m/e: 577.3 [M+H]⁺.

Example 8[(3R,4S)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester the title compound was prepared from[(3R,4S)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 1-(6-bromopyridin-3-yl)ethanone asoff-white solid. MS m/e: 593.4 [M+H]⁺.

Example 9[(3R,4S)-4-(4-Chloro-phenyl)-1-(4′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester the title compound was prepared from[(3R,4S)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 2-bromoisonicotinonitrile as off-whitesolid. MS m/e: 576.3 [M+H]⁺.

Example 10[(3R,4S)-4-(4-Chloro-phenyl)-1-(5′-methanesulfonyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester the title compound was prepared from[(3R,4S)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 2-bromo-5-(methylsulfonyl)pyridine asoff-white solid. MS m/e: 629.3 [M+H]⁺.

Example 11{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrazin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester the title compound was prepared from[(3R,4S)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 5-bromopyrazine-2-carbonitrile asoff-white solid. MS m/e: 577.3 [M+H]⁺.

Example 12{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(6-cyano-pyridazin-3-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester the title compound was prepared from[(3R,4S)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 6-chloropyridazine-3-carbonitrile asoff-white solid. MS m/e: 577.3 [M+H]⁺.

Example 13{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

a)[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3R,4S)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester the title compound was prepared from4-{(3R,4S)-3-(4-Chloro-phenyl)-4-[ethyl-(4-fluoro-phenoxycarbonyl)-amino]-pyrrolidine-1-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester through cleavage of the protecting group with TFA.The title compound was obtained as yellow foam. MS m/e: 474.3 [M+H]⁺.

b){(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester the title compound was prepared from)[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 6-chloropyridazine-3-carbonitrile asoff-white solid. MS m/e: 577.3 [M+H]⁺.

Example 14[(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester the title compound was prepared from)[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 1-(6-bromopyridin-3-yl)ethanone asoff-white solid. MS m/e: 593.4 [M+H]⁺.

Example 15[(3S,4R)-4-(4-Chloro-phenyl)-1-(4′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester the title compound was prepared from)[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 2-bromoisonicotinonitrile as off-whitesolid. MS m/e: 576.3 [M+H]⁺.

Example 16[(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-methanesulfonyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester the title compound was prepared from)[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 2-bromo-5-(methylsulfonyl)pyridine asoff-white solid. MS m/e: 629.3 [M+H]⁺.

Example 17{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrazin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester the title compound was prepared from)[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 5-bromopyrazine-2-carbonitrile asoff-white solid. MS m/e: 577.3 [M+H]⁺.

Example 18{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(6-cyano-pyridazin-3-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester the title compound was prepared from[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 6-chloropyridazine-3-carbonitrile asoff-white solid. MS m/e: 577.3 [M+H]⁺.

Example 19[(3R,4S)-4-(4-Chloro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

and

Example 20[(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

a)rac-[(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

A mixture of 125 mg (0.456 mmol)rac-[(3S,4R)-4-(4-Chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic acid4-fluoro-phenyl ester, 198 mg (0.547 mmol)1-(5-(trifluoromethyl)pyridin-2-yl)piperidine-4-carboxylic acid, 208 mg(0.547 mmol) HATU and 353 mg (2.73 mmol) DIPEA in 10 mL DMF and stirredfor 1 h ar room temperature. The mixture was concentrated and DMF andDIPEA was added and subjected to purification by preparative HPLC onreversed phase eluting with a gradient formed from acetonitrile, waterand NEt₃. The product containing fractions were evaporated to yield 187mg (66%) of the title compound as light brown viscous oil. MS m/e: 619.4[M+H]⁺.

The racemic material was subjected to separation on CHIRALPAK AD elutingwith i-propanol/heptane.[(3R,4S)-4-(4-Chloro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester was obtained as light yellow solid. MS m/e:619.4 [M+H]⁺ and[(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester was obtained as light yellow solid. MS m/e:619.4 [M+H]⁺

Example 21[(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester the title compound was prepared fromrac-[(3S,4R)-4-(4-Chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic acid4-fluoro-phenyl ester and 1-(5-cyanopyridin-2-yl)piperidine-4-carboxylicacid with subsequent separation via chiral chromatography on ChiralpakAD as off-white solid. MS m/e: 576.3 [M+H]⁺

Example 22[(3R,4S)-4-(4-Chloro-phenyl)-1-(5′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester the title compound was prepared fromrac-[(3S,4R)-4-(4-Chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic acid4-fluoro-phenyl ester and 1-(5-cyanopyridin-2-yl)piperidine-4-carboxylicacid with subsequent separation via chiral chromatography on ChiralpakAD as off-white solid. MS m/e: 576.3 [M+H]⁺

Example 23[(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-isopropyl-carbamicacid 4-fluoro-phenyl ester

a)rac-[(3S,4R)-1-Benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-isopropyl-carbamicacid 4-fluoro-phenyl ester

A mixture of 3.1 g (10.8 mmol)rac-(3S,4R)-1-benzyl-4-(4-chlorophenyl)pyrrolidin-3-amine, 785 mg (13.5mmol) acetone, 974 mg (16.2 mmol) acetic acid and 3.44 g (16.2 mmol)sodium triacteoxyborohydride in 50 mL THF was stirred for 4 h at roomtemperature. Water and Na₂CO₃ aq. was added and the mixture wasextracted with ethyl acetate. The organic layer was washed with brine,dried with Na₂SO₄, filtered off and evaporated to dryness. The residuewas dissolved in 50 mL DCM and 1.75 g (13.5 mmol) DIPEA and 13.2 mg (0.1mmol) DMAP was added. The mixture was cooled to 0-5° C. and 2.08 g (11.9mmol) 4-fluorophenyl chloroformate in 20 mL DCM was added. The mixturewas stirred at room temperature over night and evaporated to dryness.The residue was purified by flash column chromatography on silicaeluting with a gradient formed from TBME and heptane. The productcontaining fractions were evaporated to yield 3.1 g (61%) of the titlecompound as light yellow viscous oil. MS m/e: 467.2 [M+H]⁺

b)4-{(3R,4S)-3-(4-Chloro-phenyl)-4-[(4-fluoro-phenoxycarbonyl)-isopropyl-amino]-pyrolidine-1-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester

and

4-{(3S,4R)-3-(4-Chloro-phenyl)-4-[(4-fluoro-phenoxycarbonyl)-isopropyl-amino]-pyrrolidine-1-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester

In analogy to the procedure described for the synthesis ofrac-4-{(3R,4S)-3-(4-Chloro-phenyl)-4-[ethyl-(4-fluoro-phenoxycarbonyl)-amino]-pyrrolidine-1-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester the title compounds were prepared fromrac-[(3S,4R)-1-Benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-isopropyl-carbamicacid 4-fluoro-phenyl ester by cleavage of the benzyl group andsubsequent coupling with 1-(tert-butoxycarbonyl)piperidine-4-carboxylicacid. The resultingrac-4-{(3S,4R)-3-(4-Chloro-phenyl)-4-[(4-fluoro-phenoxycarbonyl)-isopropyl-amino]-pyrrolidine-1-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester was subjected to separation by chiral HPLC onCHIRALPAK AD eluting with i-propanol/heptane. After evaporation of theproduct containing fractions4-{(3S,4R)-3-(4-Chloro-phenyl)-4-[(4-fluoro-phenoxycarbonyl)-isopropyl-amino]-pyrrolidine-1-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester was obtained as yellow viscous oil. MS m/e: 588.3[M+H]⁺.4-{(3R,4S)-3-(4-Chloro-phenyl)-4-[(4-fluoro-phenoxycarbonyl)-isopropyl-amino]-pyrrolidine-1-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester was obtained as yellow viscous oil. MS m/e: 588.3[M+H]⁺.

c)[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-isopropyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3R,4S)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester the title compound was prepared from4-{(3R,4S)-3-(4-Chloro-phenyl)-4-[(4-fluoro-phenoxycarbonyl)-isopropyl-amino]-pyrrolidine-1-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester through cleavage of the protecting group with TFA.The title compound was obtained as off-white foam. MS m/e: 488.3 [M+H]⁺.

d)[(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-isopropyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester the title compound was prepared from[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-isopropyl-carbamicacid 4-fluoro-phenyl ester and 6-bromonicotinonitrile as off-whitesolid. MS m/e: 590.4 [M+H]⁺.

Example 24[(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-isopropyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester the title compound was prepared from[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-isopropyl-carbamicacid 4-fluoro-phenyl ester and 1-(6-bromopyridin-3-yl)ethanone asoff-white solid. MS m/e: 607.3 [M+H]⁺.

Example 25[(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-isopropyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester the title compound was prepared from[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-isopropyl-carbamicacid 4-fluoro-phenyl ester and 2-bromo-5-(trifluoromethyl)pyridine asoff-white solid. MS m/e: 633.4 [M+H]⁺.

Example 26{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(6-cyano-pyridazin-3-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-isopropyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester the title compound was prepared from[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-isopropyl-carbamicacid 4-fluoro-phenyl ester and 6-chloropyridazine-3-carbonitrile aslight brown solid. MS m/e: 591.3 [M+H]⁺.

Example 27{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrazin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-isopropyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester the title compound was prepared from[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-isopropyl-carbamicacid 4-fluoro-phenyl ester and 5-chloropyrazine-2-carbonitrile as lightbrown solid. MS m/e: 591.3 [M+H]⁺.

Example 28[(3R,4S)-4-(4-Chloro-phenyl)-1-(5′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-isopropyl-carbamicacid 4-fluoro-phenyl ester

a)[(3R,4S)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-isopropyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3R,4S)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester the title compound was prepared from4-{(3S,4R)-3-(4-Chloro-phenyl)-4-[(4-fluoro-phenoxycarbonyl)-isopropyl-amino]-pyrrolidine-1-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester through cleavage of the protecting group with TFA.The title compound was obtained as off-white foam. MS m/e: 488.3 [M+H]⁺.

b)[(3R,4S)-4-(4-Chloro-phenyl)-1-(5′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-isopropyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester the title compound was prepared from[(3R,4S)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-isopropyl-carbamicacid 4-fluoro-phenyl ester and 6-bromonicotinonitrile as off-whitesolid. MS m/e: 590.2 [M+H]⁺.

Example 29[(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-cyclopropyl-carbamicacid 4-fluoro-phenyl ester

a)rac-[(3S,4R)-1-Benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-cyclopropyl-amine

A mixture of 3.75 g (13.1 mmol)rac-(3S,4R)-1-benzyl-4-(4-chlorophenyl)pyrrolidin-3-amine, 3.14 g (52mmol) acetic acid and 2.62 g (15 mmol) (1-ethoxycyclopropoxy)trimethylsilane in 15 mL methanol was stirred 1 h at room temperatureand 3 h at reflux and evaporated to dryness. The residue was taken up in35 mL THF and added to a mixture formed from 989 mg (26 mmol) sodiumborohydride in 15 mL THF which was treated at 0-5° C. with 3.7 g (26mmol) boron trifluoride etherate and stirred 1 h. The mixture wasstirred at room temperature over night, water and 4N NaOH aq. was addedand extracted with ethyl acetate. The organic layer were washed withbrine, dried with Na₂SO₄, filtered off and evaporated to dryness. Theresidue was purified with flash column chromatography on silica elutingwith a gradient formed from DCM, methanol and NEt₃. The productcontaining fractions were evaporated to yield 2.27 g (53%) of the titlecompound as light brown oil. MS m/e: 327.1 [M+H]⁺.

b)rac-[(3S,4R)-1-Benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-cyclopropyl-carbamicacid 4-fluoro-phenyl ester

A mixture of 2.27 g (6.94 mmol)rac-[(3S,4R)-1-Benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-cyclopropyl-amine,987 mg (7.64 mmol) DIPEA, 8.48 mg (0.07 mmol) DMAP and 1.27 g (7.29mmol) 4-fluorophenyl chloroformate in 40 mL DCM at 0° C. was stirred atroom temperature over night and evaporated to dryness. the residue waspurified by column chromatography on silica eluting with a gradientformed from TBME and heptane. The product containing fractions wereevaporated to yield 1.64 g (51%) of the title compound as colorlessviscous oil. MS m/e: 465.1 [M+H]⁺.

c)4-{(3S,4R)-3-(4-Chloro-phenyl)-4-[cyclopropyl-(4-fluoro-phenoxycarbonyl)-amino]-pyrolidine-1-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester

and

4-{(3R,4S)-3-(4-Chloro-phenyl)-4-[cyclopropyl-(4-fluoro-phenoxycarbonyl)-amino]-pyrolidine-1-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester

In analogy to the procedure described for the synthesis ofrac-4-{(3R,4S)-3-(4-Chloro-phenyl)-4-[ethyl-(4-fluoro-phenoxycarbonyl)-amino]-pyrrolidine-1-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester the title compounds were prepared fromrac-[(3S,4R)-1-Benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-cyclopropyl-carbamicacid 4-fluoro-phenyl ester by cleavage of the benzyl group andsubsequent coupling with 1-(tert-butoxycarbonyl)piperidine-4-carboxylicacid. The resultingrac-4-{(3R,4S)-3-(4-Chloro-phenyl)-4-[cyclopropyl-(4-fluoro-phenoxycarbonyl)-amino]-pyrrolidine-1-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester was subjected to separation by chiral HPLC onCHIRALPAK AD eluting with i-propanol/heptane. After evaporation of theproduct containing fractions4-{(3S,4R)-3-(4-Chloro-phenyl)-4-[cyclopropyl-(4-fluoro-phenoxycarbonyl)-amino]-pyrrolidine-1-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester was obtained as light brown foam. MS m/e: 586.3[M+H]⁺.4-{(3R,4S)-3-(4-Chloro-phenyl)-4-[cyclopropyl-(4-fluoro-phenoxycarbonyl)-amino]-pyrrolidine-1-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester was obtained as yellow viscous oil. MS m/e: 586.3[M+H]⁺.

d)[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-cyclopropyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3R,4S)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester the title compound was prepared from4-{(3R,4S)-3-(4-Chloro-phenyl)-4-[cyclopropyl-(4-fluoro-phenoxycarbonyl)-amino]-pyrrolidine-1-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester through cleavage of the protecting group with TFA.The title compound was obtained as light yellow foam. MS m/e: 486.4[M+H]⁺.

e)[(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-cyclopropyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester the title compound was prepared from[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-cyclopropyl-carbamicacid 4-fluoro-phenyl ester and 6-bromonicotinonitrile as off-whitesolid. MS m/e: 588.2 [M+H]⁺.

Example 30[(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-cyclopropyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester the title compound was prepared from[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-cyclopropyl-carbamicacid 4-fluoro-phenyl ester and 1-(6-bromopyridin-3-yl)ethanone asoff-white solid. MS m/e: 605.3 [M+H]⁺.

Example 31[(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-cyclopropyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester the title compound was prepared from[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-cyclopropyl-carbamicacid 4-fluoro-phenyl ester and 2-bromo-5-(trifluoromethyl)pyridine asoff-white solid. MS m/e: 631.4 [M+H]⁺.

Example 32{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(6-cyano-pyridazin-3-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-cyclopropyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester the title compound was prepared from[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-cyclopropyl-carbamicacid 4-fluoro-phenyl ester and 6-chloropyridazine-3-carbonitrile asoff-white solid. MS m/e: 589.3 [M+H]⁺.

Example 33{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrazin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-cyclopropyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester the title compound was prepared from[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-cyclopropyl-carbamicacid 4-fluoro-phenyl ester and 5-chloropyrazine-2-carbonitrile as pinksolid. MS m/e: 589.3 [M+H]⁺.

Example 34[(3R,4S)-4-(4-Chloro-phenyl)-1-(5′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-cyclopropyl-carbamicacid 4-fluoro-phenyl ester

a)[(3R,4S)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-cyclopropyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3R,4S)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester the title compound was prepared from4-{(3S,4R)-3-(4-Chloro-phenyl)-4-[cyclopropyl-(4-fluoro-phenoxycarbonyl)-amino]-pyrrolidine-1-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester through cleavage of the protecting group with TFA.The title compound was obtained as light yellow foam. MS m/e: 486.4[M+H]⁺.

b)[(3R,4S)-4-(4-Chloro-phenyl)-1-(5′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-cyclopropyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester the title compound was prepared from[(3R,4S)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-cyclopropyl-carbamicacid 4-fluoro-phenyl ester and 6-bromonicotinonitrile as off-whitesolid. MS m/e: 588.2 [M+H]⁺.

Example 35[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

a) rac-(3S,4R)-1-Benzyl-4-(4-fluoro-phenyl)-pyrrolidin-3-ylamine

In analogy to the procedure described for the synthsis ofrac-(3S,4R)-1-Benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-ylamine(example 1, step a & b) the title compound was prepared fromN-(methoxymethyl)-N-(phenylmethyl)-N-(trimethylsilyl)methylamine and1-Fluoro-4-((E)-2-nitro-vinyl)-benzene subsequently reducing theNO₂-function with tin chloride. MS m/e: 271.4 [M+H]⁺.

b)rac-[(3S,4R)-1-Benzyl-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-amine

A mixture of 38 g (141 mmol)rac-(3S,4R)-1-Benzyl-4-(4-fluoro-phenyl)-pyrrolidin-3-ylamine, 7.12 g(162 mmol) acetaldehyde, 12.1 mL acetic acid and 44.7 g (211 mmol)sodium triacetoxyborohydride in 400 mL THF was stirred for 3 h at 0° C.and then warmed to room temperature. Water, Na₂CO₃ aq. and ethyl acetatewas added. The organic layer was washed with brine, dried with Na₂SO₄,filtered and evaporated to dryness. The residue was purified by columnchromatograpghy on silica eluting with a gradient formed from ethylacetate, heptane and NEt₃. The product containing fractions wereevaporated to yield 18.5 g (44%) of the title compound as brown oil. MSm/e: 299.4 [M+H]⁺.

c)rac-[(3S,4R)-1-Benzyl-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In anolgy to the procedure described for the synthesis ofrac-{(3S,4R)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester (example 1, step h) the title compound wasprepared fromrac-[(3S,4R)-1-Benzyl-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-amineand 4-fluorophenyl chloroformate as light brown viscous oil. MS m/e:437.3 [M+H]⁺.

d) [(3S,4R)-1-Benzyl-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

rac-[(3S,4R)-1-Benzyl-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester was subjected to separation by columnchromatography on Chiralpak AD eluting with hexane and i-propanol. Theproduct containing fractions were evaporated to yield the title compoundas light brown viscous oil. MS m/e: 437.3 [M+H]⁺.

and

[(3R,4S)-1-Benzyl-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

rac-[(3S,4R)-1-Benzyl-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester was subjected to separation by columnchromatography on Chiralpak AD eluting with hexane and i-propanol. Theproduct containing fractions were evaporated to yield the title compoundas light brown viscous oil. MS m/e: 437.3 [M+H]⁺.

e) Ethyl-[(3S,4R)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-carbamic acid4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis ofrac-(3S,4R)-[4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-carbamic acidtert-butyl ester (example 1, step d) the title compound was preparedfrom[(3S,4R)-1-Benzyl-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester through cleavage of the benzyl protectinggroup as brown foam. MS m/e: 347.1 [M+H]⁺.

f)[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

A mixture of 125 mg (0.36 mmol)ethyl-[(3S,4R)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-carbamic acid4-fluoro-phenyl ester, 137 mg (0.36 mmol) HATU, 63 uL (0.36 mmol) DIPEAand 69.4 mg (0.3 mmol)5′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carboxylic acid in 4mL DMF was shaken for 2 h at room temperature. The mixture was subjectedto purification by preparative HPLC on reversed phase eluting with agradient formed from acetonitrile, water and NEt₃. The productcontaining fractions were evaporated to yield 106 mg (63%) of the titlecompound as off-white solid. MS m/e: 560.2 [M+H]⁺.

Example 36[(3S,4R)-1-(5′-Chloro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35) the title compound was preparedfrom ethyl-[(3S,4R)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-carbamic acid4-fluoro-phenyl ester and1-(5-chloropyridin-2-yl)piperidine-4-carboxylic acid. MS m/e: 569.3[M+H]⁺.

Example 37Ethyl-[(3S,4R)-4-(4-fluoro-phenyl)-1-(5′-methanesulfonyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-carbamicacid 4-fluoro-phenyl ester

a)4-[(3S,4R)-3-[Ethyl-(4-fluoro-phenoxycarbonyl)-amino]-4-(4-fluoro-phenyl)-pyrrolidine-1-carbonyl]-piperidine-1-carboxylicacid tert-butyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35) the title compound was preparedfrom ethyl-[(3S,4R)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-carbamic acid4-fluoro-phenyl ester and 1-(tert-butoxycarbonyl)piperidine-4-carboxylicacid. MS m/e: 558.4 [M+H]⁺.

b)Ethyl-[(3S,4R)-4-(4-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3R,4S)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 7, step f) the title compound wasprepared from4-[(3S,4R)-3-[Ethyl-(4-fluoro-phenoxycarbonyl)-amino]-4-(4-fluoro-phenyl)-pyrrolidine-1-carbonyl]-piperidine-1-carboxylicacid tert-butyl ester through cleavage of the Boc-group with TFA. MSm/e: 458.4 [M+H]⁺.

c)Ethyl-[(3S,4R)-4-(4-fluoro-phenyl)-1-(5′-methanesulfonyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester (example 7, step g) the title compound wasprepared fromethyl-[(3S,4R)-4-(4-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-carbamicacid 4-fluoro-phenyl ester and 2-bromo-5-(methylsulfonyl)pyridine. MSm/e: 613.2 [M+H]⁺.

Example 38[(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester (example 7, step g) the title compound wasprepared fromethyl-[(3S,4R)-4-(4-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-carbamicacid 4-fluoro-phenyl ester and 1-(6-bromopyridin-3-yl)ethanone. MS m/e:577.3 [M+H]⁺.

Example 394-{(3R,4S)-3-(4-Chloro-3-fluoro-phenyl)-4-[ethyl-(4-fluoro-phenoxycarbonyl)-amino]-pyrrolidine-1-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester

a) (4-Chloro-3-fluoro-phenyl)-propynoic acid ethyl ester

To a mixture of 4-chloro-3-fluoroiodobenzene (74.27 g, 284 mmol) andcesium carbonate (185.0 g, 568 mmol) in tetrahydrofuran (730 mL) wasadded under an argon atmosphere cuprous iodide (2.16 g, 11.4 mmol) andbis(triphenylphosphine)palladium (II) chloride (3.98 g, 5.7 mmol). Ethylpropiolate (57.0 g, 575 mmol) was added dropwise over a period of 20min. The resulting dark brown suspension was stirred for 38 h at 35° C.,then filtrated over Hyflo® and the residue was washed withtetrahydrofuran (285 ml). The filtrate was evaporated and purificationof the residue by chromatography (SiO₂, heptane: ethyl acetate=90:10)afforded the title compound (57.1 g, 89%) as a yellow liquid. MS m/e:226.0 [M]⁺.

b)1-Benzyl-4-(4-chloro-3-fluoro-phenyl)-2,5-dihydro-1H-pyrrole-3-carboxylicacid

To a solution of (4-chloro-3-fluoro-phenyl)-propynoic acid ethyl ester(57.08 g, 252 mmol) in dichloromethane (240 mL) was addedtrifluoroacetic acid (1.9 mL, 25.2 mmol). The reaction mixture wascooled with a water bath at ambient temperature and a solution ofN-(methoxymethyl)-N-(trimethylsilylmethyl)benzylamine (93.43 g, 378mmol) in dichloromethane (185 mL) was added dropwise over a period of 3h. After stirring for 20 h at ambient temperature furtherN-(methoxymethyl)-N-(trimethylsilylmethyl)benzylamine (15.6 g, 63.0mmol) in dichloromethane (30 mL) was added and stirring was continuedfor another 4 h. The solvent was removed and the residue was dissolvedin dioxane (540 mL). After addition of water (270 mL) and aqueous sodiumhydroxide (32%, 64.8 ml, 700 mmol), it was stirred for 44 h at ambienttemperature. After concentration the resulting residue was diluted withwater (225 mL) and extracted with tert-butylmethylether (225 mL). Theorganic layer was washed with water (225 mL) and the aqueous layer wascooled to 5° C. and set to pH=1.5 with aqueous hydrogen chloride (25%,112 mL). After stirring for 1 h at 5° C., the resulting solid wasfiltered and washed with water (795 mL) and ethanol (225 mL). Dryinggave a light yellow solid which was stirred with ethanol (4 L) for 1 hat 85° C. The resulting suspension was filtered and the filtrate wasconcentrated. Trituration with tert-butylmethylether (2 L) afforded thetitle compound (62.34 g, 67%) as an off-white solid. MS m/e: 330.1[M−H]⁻.

c)(3R,4R)-1-Benzyl-4-(4-chloro-3-fluoro-phenyl)-pyrrolidine-3-carboxylicacid

An autoclave was charged under argon in a glove box (O₂ content <2 ppm)with1-Benzyl-4-(4-chloro-3-fluoro-phenyl)-2,5-dihydro-1H-pyrrole-3-carboxylicacid (1.00 g, 3.01 mmol), [Ru(OAc)₂((S)-2-furyl-MeOBIPHEP)] (9.18 mg,0.012 mmol)(2-furyl-MeOBIPHEP=(6,6′-dimethoxybiphenyl-2,2′-diyl)bis(di-2-furylphosphine)and methanol (30 mL). The asymmetric hydrogenation was run for 20 h at30° C. under 40 bar of hydrogen. After the pressure was released, thegrey suspension was evaporated to dryness to yield the crude titlecompound. MS m/e: 332.1 [M−H].

d)(3S,4R)-1-Benzyl-4-(4-chloro-3-fluoro-phenyl)-pyrrolidine-3-carboxylicacid

A mixture of 48.8 g (146 mmol)(3R,4R)-1-Benzyl-4-(4-chloro-3-fluoro-phenyl)-pyrrolidine-3-carboxylicacid and 15.6 mL sulfuric acid in 400 mL methanol was heated to refluxfor 21 h and evaporated. the residue was diluted with ice-water andextracted with ethyl acetate. the combined organic layers were washedwith brine, dried with Na₂SO₄, filtered and evaporated to dryness. Theresidue was purified by column chromatography on silica eluting withethyl acetate and heptane. The intermediate was dissolved in 500 mLmethanol and 4.06 mL sodium methoxide (5.4N in methanol) was added andstirred at room temperature overnight. Another 31.3 ml, sodium methoxide(5.4N in methanol) was added and stirred for 1 h at room temperature.Water was added and the mixture was stirred for 2 h at room temperature.After evaporation of methanol, water was added and th pH was adjusted to6-7 with acetic acid. The product precipitated and the mixture wasdecanted. The organic layer from the extraction with THF and ethylacetate was washed with brine, dried with Na₂SO₄, filtered andevaporated to dryness. The residue was washed with hexane and diethylether and filtered to yield after drying 44 g (49%) of the titlecompound as colorless solid. MS m/e: 334.3 [M+H]⁺.

e)[(3S,4R)-1-Benzyl-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-yl]-carbamicacid tert-butyl ester

A mixture of 44 g (132 mmol)(3S,4R)-1-Benzyl-4-(4-chloro-3-fluoro-phenyl)-pyrrolidine-3-carboxylicacid, 25.3 mL (145 mmol) DIPEA and 45.3 g (165 mmol) diphenylphosphorylazide in 600 mL tert.-butanol was heated to reflux for 16 h. Aftercooling to room temperature the mixture was evaporated to dryness. Theresidue was adsorbed on isolute HM-N and purified by columnchromatography on silica eluting with a gradient formed from heptane andethyl acetate. The product containing fraction were evaporated to yield25 g (47%) of the title compound as light brown solid. MS m/e: 405.4[M+H]⁺.

f) (3S,4R)-1-Benzyl-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-ylamine

In analogy to the procedure described for the synthesis ofrac-(3S,4R)-[3-Amino-4-(3,4-dichloro-phenyl)-pyrrolidin-1-yl]-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-yl]-methanone(example 1, step f) the title compound was prepared from[(3S,4R)-1-Benzyl-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-yl]-carbamicacid tert-butyl ester through cleavage of the Boc-group with TFA. MSm/e: 305.2 [M+H]⁺.

g)[(3S,4R)-1-Benzyl-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis ofrac-{(3S,4R)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester (example 1, step g & h) the title compoundwas prepared from(3S,4R)-1-Benzyl-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-ylaminethrough reductive amination with acetaldehyde followed by reaction with4-fluorophenyl chloroformate to yield the title compound as light brownoil. MS m/e: 471.2 [M+H]⁺.

h) [(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis ofrac-(3S,4R)-[4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-carbamic acidtert-butyl ester (example 1, step d) the title compound was preparedfrom[(3S,4R)-1-Benzyl-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester through cleavage of the benzyl-group as brownfoam which was used in the consecutive step without furtherpurification. MS m/e: 381.3 [M+H]⁺.

i)4-{(3R,4S)-3-(4-Chloro-3-fluoro-phenyl)-4-[ethyl-(4-fluoro-phenoxycarbonyl)-amino]-pyrrolidine-1-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35) the title compound was preparedfrom[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid. MS m/e: 592.4[M+H]⁺.

Example 40[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(5′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

a)[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3R,4S)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 7, step f) the title compound wasprepared from4-{(3R,4S)-3-(4-Chloro-3-fluoro-phenyl)-4-[ethyl-(4-fluoro-phenoxycarbonyl)-amino]-pyrrolidine-1-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester through cleavage of the Boc-group with TFA. MSm/e: 492.2 [M+H]⁺.

b)[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(5′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester (example 7, step g) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and1-(5-cyanopyridin-2-yl)piperidine-4-carboxylic acid. MS m/e: 594.3[M+H]⁺.

Example 41[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(5′-chloro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and1-(5-chloropyridin-2-yl)piperidine-4-carboxylic acid. MS m/e: 603.2[M+H]⁺.

Example 42[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and1-(5-(trifluoromethyl)pyridin-2-yl)piperidine-4-carboxylic acid. MS m/e:637.3 [M+H]⁺.

Example 43[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(6′-cyano-3,4,5,6-tetrahydro-2H-[1,3′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and1-(5-(trifluoromethyl)pyridin-2-yl)piperidine-4-carboxylic acid. MS m/e:594.3 [M+H]⁺.

Example 44{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and1-(1-methylcyclopropanecarbonyl)piperidine-4-carboxylic acid. MS m/e:574.5 [M+H]⁺.

Example 45[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(4′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and1-(4-cyanopyridin-2-yl)piperidine-4-carboxylic acid. MS m/e: 594.3[M+H]⁺.

Example 46[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(5′-fluoro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and1-(5-fluoropyridin-2-yl)piperidine-4-carboxylic acid. MS m/e: 587.2[M+H]⁺.

Example 47[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(5′-methyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and1-(5-methylpyridin-2-yl)piperidine-4-carboxylic acid. MS m/e: 583.2[M+H]⁺.

Example 48[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

a) (3,4-Difluoro-phenyl)-propynoic acid ethyl ester

In analogy to the procedure described for the synthesis of(4-Chloro-3-fluoro-phenyl)-propyonic acid ethyl ester (example 39, stepa) the title compound was prepared from 3,4-difluoroiodobenzene andethyl propionate as yellow liquid. MS m/e: 210 [M+H]⁺.

b) 1-Benzyl-4-(3,4-difluoro-phenyl)-2,5-dihydro-1H-pyrrole-3-carboxylicacid

In analogy to the procedure described for the synthesis of1-Benzyl-4-(4-chloro-3-fluoro-phenyl)-2,5-dihydro-1H-pyrrole-3-carboxylicacid (example 39, step b) the title compound was prepared from(3,4-Difluoro-phenyl)-propynoic acid ethyl ester andN-(methoxymethyl)-N-(trimethylsilylmethyl)benzylamine. MS m/e: 314.1[M−H]⁻.

c) (3R,4R)-1-Benzyl-4-(3,4-difluoro-phenyl)-pyrrolidine-3-carboxylicacid

In analogy to the procedure described for the synthesis of(3R,4R)-1-Benzyl-4-(4-chloro-3-fluoro-phenyl)-pyrrolidine-3-carboxylicacid (example 39, step c) the title compound was prepared from1-Benzyl-4-(3,4-difluoro-phenyl)-2,5-dihydro-1H-pyrrole-3-carboxylicacid through asymmetric hydrogenation.

d) (3S,4R)-1-Benzyl-4-(3,4-difluoro-phenyl)-pyrrolidine-3-carboxylicacid

In analogy to the procedure described for the synthesis of(3S,4R)-1-Benzyl-4-(4-chloro-3-fluoro-phenyl)-pyrrolidine-3-carboxylicacid (example 39, step d) the title compound was prepared from(3R,4R)-1-Benzyl-4-(3,4-difluoro-phenyl)-pyrrolidine-3-carboxylic acidas white solid. MS m/e: 318.1 [M+H]⁺.

e) [(3S,4R)-1-Benzyl-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-carbamicacid tert-butyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-Benzyl-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-yl]-carbamicacid tert-butyl ester (example 39, step e) the title compound wasprepared from(3S,4R)-1-Benzyl-4-(3,4-difluoro-phenyl)-pyrrolidine-3-carboxylic acidas off-white solid. MS m/e: 389.3 [M+H]⁺.

f) (3S,4R)-1-Benzyl-4-(3,4-difluoro-phenyl)-pyrrolidin-3-ylamine

In analogy to the procedure described for the synthesis of(3S,4R)-1-Benzyl-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-ylamine(example 39, step f) the title compound was prepared from[(3S,4R)-1-Benzyl-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-carbamic acidtert-butyl ester as brown oil. MS m/e: 289.2 [M+H]⁺.

g)[(3S,4R)-1-Benzyl-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-Benzyl-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (exymple 39, step g) the title compound wasprepared from(3S,4R)-1-Benzyl-4-(3,4-difluoro-phenyl)-pyrrolidin-3-ylamine as lightyellow oil. MS m/e: 455.3 [M+H]⁺.

h) [(3S,4R)-4-(3,4-Difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic acid4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 39, step h) the title compound wasprepared from[(3S,4R)-1-Benzyl-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester as brown foam. MS m/e: 365.3 [M+H]⁺.

i)[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35) the title compound was preparedfrom [(3S,4R)-4-(3,4-Difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and1-(5-cyanopyridin-2-yl)piperidine-4-carboxylic acid. MS m/e: 578.3[M+H]⁺.

Example 49[(3S,4R)-1-(5′-Chloro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35) the title compound was preparedfrom [(3S,4R)-4-(3,4-Difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and1-(5-chloropyridin-2-yl)piperidine-4-carboxylic acid. MS m/e: 587.2[M+H]⁺.

Example 50[(3S,4R)-4-(3,4-Difluoro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(3,4-Difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic acid4-fluoro-phenyl ester and1-(5-(trifluoromethyl)pyridin-2-yl)piperidine-4-carboxylic acid. MS m/e:612.4 [M+H]⁺.

Example 51[(3S,4R)-1-(6′-Cyano-3,4,5,6-tetrahydro-2H-[1,3′]bipyridinyl-4-carbonyl)-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(3,4-Difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic acid4-fluoro-phenyl ester and 1-(6-cyanopyridin-3-yl)piperidine-4-carboxylicacid. MS m/e: 578.3 [M+H]⁺.

Example 52{(3S,4R)-4-(3,4-Difluoro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(3,4-Difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic acid4-fluoro-phenyl ester and1-(1-methylcyclopropanecarbonyl)piperidine-4-carboxylic acid. MS m/e:558.3 [M+H]⁺.

Example 53[(3S,4R)-1-(4′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(3,4-Difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic acid4-fluoro-phenyl ester and 1-(4-cyanopyridin-2-yl)piperidine-4-carboxylicacid. MS m/e: 578.4 [M+H]⁺.

Example 54[(3S,4R)-4-(3,4-Difluoro-phenyl)-1-(5′-fluoro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(3,4-Difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic acid4-fluoro-phenyl ester and1-(5-fluoropyridin-2-yl)piperidine-4-carboxylic acid. MS m/e: 571.4[M+H]⁺.

Example 55[(3S,4R)-4-(3,4-Difluoro-phenyl)-1-(5′-methyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(3,4-Difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic acid4-fluoro-phenyl ester and1-(5-methylpyridin-2-yl)piperidine-4-carboxylic acid. MS m/e: 567.4[M+H]⁺.

Example 56[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

a)4-{(3R,4S)-3-(4-Chloro-3-fluoro-phenyl)-4-[ethyl-(4-fluoro-phenoxycarbonyl)-amino]-pyrolidine-1-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(3,4-Difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic acid4-fluoro-phenyl ester and 1-(tert-butoxycarbonyl)piperidine-4-carboxylicacid. MS m/e: 592.4 [M+H]⁺.

b)[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3R,4S)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 7, step f) the title compound wasprepared from4-{(3R,4S)-3-(4-Chloro-3-fluoro-phenyl)-4-[ethyl-(4-fluoro-phenoxycarbonyl)-amino]-pyrrolidine-1-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester through cleavage of the Boc-group with TFA. MSm/e: 492.2 [M+H]⁺.

Example 57{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(6-cyano-pyridazin-3-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester (example 7, step g) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 6-chloropyridazine-3-carbonitrile inacetonitrile as off-white solid after purification over silica. MS m/e:595.4 [M+H]⁺.

Example 58[(3S,4R)-1-[1-(6-Cyano-pyridazin-3-yl)-piperidine-4-carbonyl]-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

a)4-{(3R,4S)-3-(3,4-Difluoro-phenyl)-4-[ethyl-(4-fluoro-phenoxycarbonyl)-amino]-pyrrolidine-1-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(3,4-Difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic acid4-fluoro-phenyl ester and 1-(tert-butoxycarbonyl)piperidine-4-carboxylicacid. MS m/e: 576.3 [M+H]⁺.

b)[(3S,4R)-4-(3,4-Difluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3R,4S)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 7, step f) the title compound wasprepared from4-{(3R,4S)-3-(3,4-Difluoro-phenyl)-4-[ethyl-(4-fluoro-phenoxycarbonyl)-amino]-pyrrolidine-1-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester through cleavage of the Boc-group with TFA. MSm/e: 492.2 [M+H]⁺.

c)[(3S,4R)-1-[1-(6-Cyano-pyridazin-3-yl)-piperidine-4-carbonyl]-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester (example 7, step g) the title compound wasprepared from[(3S,4R)-4-(3,4-Difluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 6-chloropyridazine-3-carbonitrile inacetonitrile as off-white solid after purification over silica. MS m/e:579.4 [M+H]⁺.

Example 59[(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester (example 7, step g) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 1-(6-bromopyridin-3-yl)ethanone inacetonitrile as off-white solid after purification over silica. MS m/e:611.3 [M+H]⁺.

Example 60[(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester (example 7, step g) the title compound wasprepared from[(3S,4R)-4-(3,4-Difluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 1-(6-bromopyridin-3-yl)ethanone inacetonitrile as off-white solid after purification over silica. MS m/e:595.4 [M+H]⁺.

Example 61{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(5-cyano-pyrazin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester (example 7, step g) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 5-bromopyrazine-2-carbonitrile inacetonitrile as dark brown solid after purification over silica. MS m/e:595.4 [M+H]⁺.

Example 62[(3S,4R)-1-[1-(5-Cyano-pyrazin-2-yl)-piperidine-4-carbonyl]-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester (example 7, step g) the title compound wasprepared from[(3S,4R)-4-(3,4-Difluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 5-bromopyrazine-2-carbonitrile inacetonitrile as dark brown solid after purification over silica. MS m/e:579.4 [M+H]⁺.

Example 63[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(5′-methanesulfonyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester (example 7, step g) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 2-bromo-5-(methylsulfonyl)pyridine inacetonitrile as off-white solid after purification over silica. MS m/e:647.4 [M+H]⁺.

Example 64[(3S,4R)-4-(3,4-Difluoro-phenyl)-1-(5′-methanesulfonyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester (example 7, step g) the title compound wasprepared from[(3S,4R)-4-(3,4-Difluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 2-bromo-5-(methylsulfonyl)pyridine inacetonitrile as dark brown solid after purification over silica. MS m/e:631.4 [M+H]⁺.

Example 65{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(3-methyl-oxetane-3-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 3-methyloxetane-3-carboxylic acid. MSm/e: 590.3 [M+H]⁺.

Example 66{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(3,3-difluoro-cyclobutanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 3,3-difluorocyclobutanecarboxylic acid.MS m/e: 610.2 [M+H]⁺.

Example 67[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(1-cyclobutanecarbonyl-piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and cyclobutanecarboxylic acid. MS m/e: 574.5[M+H]⁺.

Example 68{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(1-trifluoromethyl-cyclobutanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 1-(trifluoromethyl)cyclobutanecarboxylicacid. MS m/e: 642.3 [M+H]⁺.

Example 69{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(3-fluoro-cyclobutanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 3-fluorocyclobutanecarboxylic acid. MSm/e: 592.4 [M+H]⁺.

Example 70{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(2,2-difluoro-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 2,2-difluorocyclopropanecarboxylic acid.MS m/e: 596.3 [M+H]⁺.

Example 71{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(1-trifluoromethyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 1-(trifluoromethyl)cyclopropanecarboxylicacid. MS m/e: 628.4 [M+H]⁺.

Example 72{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(1-cyano-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 1-cyanocyclopropanecarboxylic acid. MSm/e: 585.3 [M+H]⁺.

Example 73{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(2,2-dimethyl-tetrahydro-pyran-4-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and2,2-dimethyltetrahydro-2H-pyran-4-carboxylic acid. MS m/e: 632.5 [M+H]⁺.

Example 74{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(5-trifluoromethyl-pyridine-2-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 5-(trifluoromethyl)picolinic acid. MSm/e: 665.2 [M+H]⁺.

Example 75{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(5-fluoro-pyridine-2-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 5-fluoropicolinic acid. MS m/e: 615.2[M+H]⁺.

Example 76{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(4-cyano-benzoyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 4-cyanobenzoic acid. MS m/e: 621.4[M+H]⁺.

Example 77{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(4-fluoro-benzoyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 4-fluorobenzoic acid. MS m/e: 614.2[M+H]⁺.

Example 78{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(5-trifluoromethyl-pyrazine-2-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 5-(trifluoromethyl)pyrazine-2-carboxylicacid. MS m/e: 666.2 [M+H]⁺.

Example 79{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(6-cyano-pyridine-3-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 6-cyanonicotinic acid. MS m/e: 622.4[M+H]⁺.

Example 80[(3S,4R)-1-(1-Acetyl-piperidine-4-carbonyl)-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and acetic acid. MS m/e: 534.2 [M+H]⁺.

Example 81[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(1-methanesulfonyl-piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

A mixture of 32 mg (0.065 mmol)[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester, 57 uL (0.325 mmol) DIPEA and 11.2 mg (0.097mmol) mesyl chloride in 1.5 mL DMF was shaken for 90 min at roomtemperature. The mixture was subjected to purification by preparativeHPLC on reversed phase eluting with a gradient formed from acetonitrile,water and NEt₃. The product containing fractions were evaporated toyield 16 mg (43%) of the title compound as off-white solid. MS m/e:570.4 [M+H]⁺.

Example 82[(3S,4R)-1-(1-Acetyl-piperidine-4-carbonyl)-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

a) [(3S,4R)-1-Benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

The title compound was prepared fromrac-[(3S,4R)-1-Benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 7, c) through chiral columnchromatography on Chiralpak AD. MS m/e: 453.3 [M+H]⁺.

b) [(3S,4R)-4-(4-Chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic acid4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of d)rac-(3S,4R)-[4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-carbamic acidtert-butyl ester (example 1, d) the title compound was prepared from[(3S,4R)-1-Benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester as light brown foam which was used crude inthe subsequent step. MS m/e: 363.2 [M+H]⁺.

c)[(3S,4R)-1-(1-Acetyl-piperidine-4-carbonyl)-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 20) the title compound was preparedfrom [(3S,4R)-4-(4-Chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic acid4-fluoro-phenyl ester and 1-acetylpiperidine-4-carboxylic acid. MS m/e:516.2 [M+H]⁺.

Example 83{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[5′-(1-hydroxy-1-methyl-ethyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

A mixture of 142 mg (0.23 mmol)[(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 59) and 0.097 mL (0.29 mmol)methylmagnesium iodide (3M) in 5 mL was stirred from 0° to 15° C. during90 min and quenched at 0° C. with NH₄Cl (aq.). The mixture was extractedwith ethyl acetate and the combined organic layers were dried withNa₂SO₄ and evaporated. The residue was subjected to preparative HPLC onreversed phase eluting with a gradient formed from acetonitrile, waterand NEt₃. The product containing fractions were evaporated to yield 19mg (13%) of the title compound as white solid. MS m/e: 627.2 [M+H]⁺.

Example 84{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(3-methyl-oxetane-3-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 2-fluoro-phenyl ester

a)rac-[(3S,4R)-1-Benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 2-fluoro-phenyl ester

In analogy to the procedure described for the synthesis ofrac-[(3S,4R)-1-Benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 7, c) the title compound wasprepared fromrac-(3S,4R)-1-benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-ylamine throughreductive amination with acetaldehyde and subsequent reaction with2-fluorophenyl chloroformate as light yellow oil. MS m/e: 453.1 [M+H]⁺.

b) [(3S,4R)-1-Benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 2-fluoro-phenyl ester

The title compound was prepared fromrac-[(3S,4R)-1-Benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 2-fluoro-phenyl ester through chiral column chromatography onChiralpak AD. MS m/e: 453.1 [M+H]⁺.

c) [(3S,4R)-4-(4-Chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic acid2-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of d)rac-(3S,4R)-[4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-carbamic acidtert-butyl ester (example 1, d) the title compound was prepared from[(3S,4R)-1-Benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 2-fluoro-phenyl ester as light brown foam which was used crude inthe subsequent step. MS m/e: 363.3 [M+H]⁺.

d)[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 2-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3R,4S)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 7, f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic acid2-fluoro-phenyl ester and 1-(tert-butoxycarbonyl)piperidine-4-carboxylicacid (coupling according to example 7, d) and subsequent removal of theBoc-protecting group (example 7, e) as light yellow foam. MS m/e: 474.2[M+H]⁺.

e){(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(3-methyl-oxetane-3-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 2-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 2-fluoro-phenyl ester and1-(1-methylcyclopropanecarbonyl)piperidine-4-carboxylic acid. MS m/e:572.2 [M+H]⁺.

Example 85{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(1-cyano-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 2-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 2-fluoro-phenyl ester and 1-cyanocyclopropanecarboxylic acid. MSm/e: 567.3 [M+H]⁺.

Example 86{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(5-trifluoromethyl-pyridine-2-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 2-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 2-fluoro-phenyl ester and 5-(trifluoromethyl)picolinic acid. MSm/e: 647.7 [M+H]⁺.

Example 87[(3S,4R)-4-(4-Chloro-phenyl)-1-(1-cyclobutanecarbonyl-piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and cyclobutanecarboxylic acid. MS m/e: 556.2[M+H]⁺.

Example 88{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(3-methyl-oxetane-3-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 3-methyloxetane-3-carboxylic acid. MSm/e: 572.2 [M+H]⁺.

Example 89{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(3-fluoro-cyclobutanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 3-fluorocyclobutanecarboxylic acid. MSm/e: 574.2 [M+H]⁺.

Example 90{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(3,3-difluoro-cyclobutanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 3,3-difluorocyclobutanecarboxylic acid.MS m/e: 592.3 [M+H]⁺.

Example 91{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(3-methoxy-cyclobutanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 3-methoxycyclobutanecarboxylic acid. MSm/e: 586.2 [M+H]⁺.

Example 92{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(1-trifluoromethyl-cyclobutanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 1-(trifluoromethyl)cyclobutanecarboxylicacid. MS m/e: 624.1 [M+H]⁺.

Example 93{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(2-cyano-acetyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 2-cyanoacetic acid. MS m/e: 541.3 [M+H]⁺.

Example 94{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(1-cyano-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 1-cyanocyclopropanecarboxylic acid. MSm/e: 567.3 [M+H]⁺.

Example 95{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(1-trifluoromethyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 1-(trifluoromethyl)cyclopropanecarboxylicacid. MS m/e: 610.2 [M+H]⁺.

Example 96{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(2,2-difluoro-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 2,2-difluorocyclopropanecarboxylic acid.MS m/e: 578.3 [M+H]⁺.

Example 97{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(tetrahydro-pyran-4-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and tetrahydro-2H-pyran-4-carboxylic acid. MSm/e: 586.3 [M+H]⁺.

Example 98{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(2,2-dimethyl-tetrahydro-pyran-4-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and2,2-dimethyltetrahydro-2H-pyran-4-carboxylic acid. MS m/e: 614.2 [M+H]⁺.

Example 99{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(1-methoxymethyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 1-(methoxymethyl)cyclopropanecarboxylicacid. MS m/e: 586.3 [M+H]⁺.

Example 100{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(2,2-dimethyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 2,2-dimethylcyclopropanecarboxylic acid.MS m/e: 570.2 [M+H]⁺.

Example 101{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(5-trifluoromethyl-pyridine-2-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 5-(trifluoromethyl)picolinic acid. MSm/e: 647.3 [M+H]⁺.

Example 102{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(5-fluoro-pyridine-2-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 5-fluoropicolinic acid. MS m/e: 597.2[M+H]⁺.

Example 103{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(6-oxo-piperidine-3-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 6-oxopiperidine-3-carboxylic acid. MSm/e: 599.2 [M+H]⁺.

Example 104{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(1-isopropyl-6-oxo-piperidine-3-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 1-isopropyl-6-oxopiperidine-3-carboxylicacid. MS m/e: 641.4 [M+H]⁺.

Example 105[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(1-isopropyl-6-oxo-piperidine-3-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 39, h) and1-isopropyl-6-oxopiperidine-3-carboxylic acid. MS m/e: 548.3 [M+H]⁺.

Example 106{(3S,4R)-4-(3,4-Difluoro-phenyl)-1-[1-((S)-4-oxo-azetidine-2-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(3,4-Difluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 58, b) and(S)-4-oxoazetidine-2-carboxylic acid. MS m/e: 573.2 [M+H]⁺.

Example 107{(3S,4R)-4-(3,4-Difluoro-phenyl)-1-[1-(6-oxo-piperidine-3-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(3,4-Difluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 58, b) and6-oxopiperidine-3-carboxylic acid. MS m/e: 601.3 [M+H]⁺.

Example 108{(3S,4R)-4-(4-Chloro-phenyl)-1-[5′-(1-hydroxy-ethyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

A mixture of 62 mg (0.1.5 mmol)[(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 14) and 3.95 mg (0.105 mmol) sodiumborohydride in 2 mL THF/0.2 mL MeOH was stirred at room temperature for45 minutes. Water was added and the mixture was extracted with ethylacetate. The combined organic layers were dried with Na₂SO₄, filteredand evaporated to dryness to yield 58 mg (93%) of the title compound asoff-white solid. MS m/e: 595.2 [M+H]⁺.

Example 109[(3S,4R)-1-(5′-Carbamoyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 39, h) and1-[5-(aminocarbonyl)pyridine-2-yl]piperidine-4-carboxylic acid. MS m/e:612.3 [M+H]⁺.

Example 110[(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-chloro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

a) [(3S,4R)-1-Benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-carbamic acidtert-butyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-Benzyl-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-carbamic acidtert-butyl ester (example 48, e) the title compound was preparedfollowing the sequence as described in example 48, b to e starting fromethyl 3-(4-chlorophenyl)propiolate andN-(methoxymethyl)-N-(trimethylsilylmethyl)benzylamine as off-whitesolid. MS m/e: 387.3 [M+H]⁺.

b) [(3S,4R)-1-Benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid tert-butyl ester

A mixture of 4.2 g (10.9 mmol)[(3S,4R)-1-Benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-carbamic acidtert-butyl ester, 521 mg (13 mmol) NaH (60%) and 2.54 g (16.3 mmol)iodoethane in 40 mL DMF was stirred for 1 h at 60° C. and evaporated todryness. The residue was taken up in ethyl acetate and water andextracted further with ethyl acetate. The combined organic layers werewashed with brine, dried with Na₂SO₄, filtered and evaporated todryness. The residue was purified by column chromatography on silicaeluting with a gradient formed from ethyl acetate and heptane to yieldafter evaporation of the product containing fractions 2.5 g (55%) of thetitle compound as light yellow viscous oil. MS m/e: 415.3 [M+H]⁺.

c) [(3S,4R)-4-(4-Chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic acid4-fluoro-phenyl ester

In analogy to the procedure described forrac-(3S,4R)-[3-Amino-4-(3,4-dichloro-phenyl)-pyrrolidin-1-yl]-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-yl]-methanone(example 1, f) the Boc protecting group was removed. The liberated aminewas reacted to the respective carbamate in analogy to the proceduredescribed for the synthesis ofrac-{(3S,4R)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester (example 1, h). The benzyl protecting groupwas removed in analogy to the procedure described forrac-(3S,4R)-[4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-carbamic acidtert-butyl ester (example 1, d) to yield the title compound as amorphouscrude brown foam. MS m/e: 363.3 [M+H]⁺.

d)[(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-chloro-3,4,5,6-tetrahydro-2H-[1,2]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic acid4-fluoro-phenyl ester and1-(5-chloropyridine-2-yl)piperidine-4-carboxylic acid. MS m/e: 585.2[M+H]⁺.

Example 111[(3S,4R)-1-(5′-Carbamoyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(4-Chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic acid4-fluoro-phenyl ester and1-[5-(aminocarbonyl)pyridine-2-yl]piperidine-4-carboxylic acid. MS m/e:594.3 [M+H]⁺.

Example 112[(3S,4R)-4-(3,4-Dichloro-phenyl)-1-(5′-fluoro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

a) [(3S,4R)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic acid4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-4-(4-Chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic acid4-fluoro-phenyl ester (example 110, c) the title compound was preparedfollowing the same sequence of transformations described in example 110starting from ethyl 3-(3,4-dichlorophenyl)propiolate andN-(methoxymethyl)-N-(trimethylsilylmethyl)benzylamine as amorphous crudebrown foam.

b)[(3S,4R)-4-(3,4-Dichloro-phenyl)-1-(5′-fluoro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic acid4-fluoro-phenyl ester and1-(5-fluoropyridin-2-yl)piperidine-4-carboxylic acid. MS m/e: 603.2[M+H]⁺.

Example 113[(3S,4R)-1-(5′-Chloro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic acid4-fluoro-phenyl ester and1-(5-chloropyridin-2-yl)piperidine-4-carboxylic acid. MS m/e: 619.3[M+H]⁺.

Example 114[(3S,4R)-4-(3,4-Dichloro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic acid4-fluoro-phenyl ester and1-(5-(trifluoromethyl)pyridin-2-yl)piperidine-4-carboxylic acid. MS m/e:653.2 [M+H]⁺.

Example 115[(3S,4R)-1-(5′-Carbamoyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic acid4-fluoro-phenyl ester and1-(5-carbamoylpyridin-2-yl)piperidine-4-carboxylic acid. MS m/e: 628.4[M+H]⁺.

Example 116[(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

a)4-{(3R,4S)-3-(3,4-Dichloro-phenyl)-4-[ethyl-(4-fluoro-phenoxycarbonyl)-amino]-pyrrolidine-1-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic acid4-fluoro-phenyl ester and 1-(tert-butoxycarbonyl)piperidine-4-carboxylicacid. MS m/e: 608.0 [M+H]⁺.

b) [(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-1-4-carbonyl)-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

After removal of the Boc-protecting group under acidic conditions, inanalogy to the procedure described for the synthesis of{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester (example 7, g) the title compound wasprepared from[(3S,4R)-4-(3,4-Dichloro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and 5-acetyl-2-bromopyridine as off-whitefoam. MS m/e: 627.3 [M+H]⁺.

Example 117[(3S,4R)-4-(3-Chloro-4-fluoro-phenyl)-1-(5′-fluoro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

a) [(3S,4R)-4-(3-Chloro-4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-4-(4-Chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic acid4-fluoro-phenyl ester (example 110, c) the title compound was preparedfollowing the same sequence of transformations described in example 110starting from (3-Chloro-4-fluoro-phenyl)-propynoic acid ethyl ester(prepared in analogy to (4-Chloro-3-fluoro-phenyl)-propynoic acid ethylester (example 39, step a)) andN-(methoxymethyl)-N-(trimethylsilylmethyl)benzylamine as amorphous crudebrown solid.

b)[(3S,4R)-4-(3-Chloro-4-fluoro-phenyl)-1-(5′-fluoro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(3-Chloro-4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and1-(5-fluoropyridin-2-yl)piperidine-4-carboxylic acid. MS m/e: 587.1[M+H]⁺.

Example 118[(3S,4R)-4-(3-Chloro-4-fluoro-phenyl)-1-(5′-chloro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(3-Chloro-4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and1-(5-chloropyridin-2-yl)piperidine-4-carboxylic acid. MS m/e: 603.2[M+H]⁺.

Example 119[(3S,4R)-4-(3-Chloro-4-fluoro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(3-Chloro-4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and1-(5-(trifluoromethyl)pyridin-2-yl)piperidine-4-carboxylic acid. MS m/e:637.3 [M+H]⁺.

Example 120[(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(3-chloro-4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasprepared from[(3S,4R)-4-(3-Chloro-4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester and1-(5-acetylpyridin-2-yl)piperidine-4-carboxylic acid. MS m/e: 611.3[M+H]⁺.

Example 121{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-((S)-4-oxo-azetidine-2-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the title compound wasfrom [(3S,4R)-4-(4-Chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic acid4-fluoro-phenyl ester and (S)-4-oxoazetidine-2-carboxylic acid. MS m/e:571.2 [M+H]⁺.

Example 122[(3S,4R)-1-[5′-(2-Diethylamino-acetyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl]-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester

A mixture of 0.17 g (0.285 mmol)[(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 38) and 84.3 mg (0.295 mmol)5,5-dibromobarbituric acid in 10 mL dioxane was heated to 85° C. for 40h. At room temperature 0.216 g (2.95 mmol) diethylamine was added andheated to 45° C. for 2 h and evaporated. the residue was taken up inmethanol and subjected to preparative HPLC on reversed phase elutingwith a gradient formed from acetonitrile, water and NEt₃. The productcontaining fractions were evaporated to yield 49 mg (26%) of the titlecompound as light brown solid. MS m/e: 648.3 [M+H]⁺.

Example 123 Acetic acid4-{(3R,4S)-3-(4-chloro-phenyl)-4-[ethyl-(4-fluoro-phenoxycarbonyl)-amino]-pyrrolidine-1-carbonyl}-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-ylester

In analogy to the procedure described for the synthesis of[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester (example 35, step f) the intermediate wasprepared from[(3S,4R)-4-(4-Chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamic acid4-fluoro-phenyl ester and1-(5-hydroxypyridin-2-yl)piperidine-4-carboxylic acid. Afterwards,acetyl chloride was added and stirring was continued for 30 min at roomtemperature. The mixture was directly subjected to preparative HPLC onreversed phase eluting with a gradient formed from acetonitrile, waterand NEt₃. The product containing fractions were evaporated to yield thetitle compound as off-white solid. MS m/e: 608.2 [M+H]⁺.

Experimental Procedure

The compounds were investigated in accordance with the tests givenhereinafter

[³H]SR142801 Competition Binding Assay

hNK3 receptor binding experiment were performed using [³H]SR142801(Catalog No. TRK1035, specific activity: 74.0 Ci/mmol, Amersham, GEHealthcare UK limited, Buckinghamshire, UK) and membrane isolated fromHEK293 cells transiently expressing recombinant human NK3 receptor.After thawing, the membrane homogenates were centrifuged at 48,000×g for10 min at 4° C., the pellets were resuspended in the 50 mM Tris-HCl, 4mM MnCl₂, 1 μM phosphoramidon, 0.1% BSA binding buffer at pH 7.4 to afinal assay concentration of 5 μg protein/well. For inhibitionexperiments, membranes were incubated with [³H]SR142801 at aconcentration equal to K_(D) value of radioligand and 10 concentrationsof the inhibitory compound (0.0003-10 μM) (in a total reaction volume of500 μl) for 75 min at room temperature (RT). At the end of theincubation, membranes were filtered onto unitfilter (96-well whitemicroplate with bonded GF/C filter preincubated 1 h in 0.3% PEI+0.3%BSA, Packard BioScience, Meriden, Conn.) with a Filtermate 196 harvester(Packard BioScience) and washed 4 times with ice-cold 50 mM Tris-HCl, pH7.4 buffer. Nonspecific binding was measured in the presence of 10 μMSB222200 for both radioligands. The radioactivity on the filter wascounted (5 min) on a Packard Top-count microplate scintillation counterwith quenching correction after addition of 45 μl of microscint 40(Canberra Packard S. A., Zürich, Switzerland) and shaking for 1 h.Inhibition curves were fitted according to the Hill equation:y=100/(1+(x/IC₅₀)^(nH)), where n_(H)=slope factor using Excel-fit 4software (Microsoft). IC₅₀ values were derived from the inhibition curveand the affinity constant (K_(i)) values were calculated using theCheng-Prussoff equation K_(i)=IC₅₀/(1+[L]/K_(D)) where [L] is theconcentration of radioligand and K_(D) is its dissociation constant atthe receptor, derived from the saturation isotherm. All experiments wereperformed in duplicate and the mean±standard error (SEM) of theindividual K_(i) values was calculated.

The results of all specific compounds with a hNK-3 receptor affinity inμM were shown in the following table 1.

TABLE 1 Example Data K_(i) [μM] 1 0.001 2 0.046 3 0.276 4 0.01 5 0.002 60.062 7 0.089 8 0.055 9 0.138 10 0.065 11 0.036 12 0.023 13 0.008 140.003 15 0.008 16 0.002 17 0.002 18 0.002 19 0.088 20 0.003 21 0.002 220.025 23 0.021 24 0.062 25 0.112 26 0.046 27 0.047 28 0.05 29 0.012 300.035 31 0.057 32 0.052 33 0.048 34 0.116 35 0.004 36 0.01 37 0.008 380.007 39 0.004 40 0.0007 41 0.0006 42 0.002 43 0.0003 44 0.002 45 0.00346 0.001 47 0.002 48 0.002 49 0.005 50 0.009 51 0.002 52 0.015 53 0.01654 0.007 55 0.009 56 0.267 57 0.0007 58 0.005 59 0.0005 60 0.004 610.0008 62 0.006 63 0.0007 64 0.005 65 0.003 66 0.001 67 0.002 68 0.00269 0.002 70 0.004 71 0.004 72 0.002 73 0.003 74 0.012 75 0.003 76 0.01777 0.004 78 0.005 79 0.008 80 0.002 81 0.029 82 0.0082 83 0.0038 840.0298 85 0.0233 86 0.0707 87 0.0021 88 0.0056 89 0.0033 90 0.0024 910.0065 92 0.0066 93 0.0071 94 0.0078 95 0.0061 96 0.0034 97 0.0044 980.0047 99 0.0047 100 0.0036 101 0.0425 102 0.0082 103 0.0326 104 0.0176105 0.0312 106 0.066 107 0.1312 108 0.0047 109 0.0017 110 0.0048 1110.0074 112 0.0008 113 0.0005 114 0.0016 115 0.0009 116 0.0005 117 0.0033118 0.0018 119 0.0037 120 0.0017 121 0.0169 122 0.0696 123 0.006

The compounds of formula I as well as their pharmaceutically usable acidaddition salts can be used as medicaments, e.g. in the form ofpharmaceutical preparations. The pharmaceutical preparations can beadministered orally, e.g. in the form of tablets, coated tablets,dragées, hard and soft gelatine capsules, solutions, emulsions orsuspensions. The administration can, however, also be effected rectally,e.g. in the form of suppositories, or parenterally, e.g. in the form ofinjection solutions.

The compounds of formula I and their pharmaceutically usable acidaddition salts can be processed with pharmaceutically inert, inorganicor organic excipients for the production of tablets, coated tablets,dragees and hard gelatine capsules. Lactose, corn starch or derivativesthereof, talc, stearic acid or its salts etc can be used as suchexcipients e.g. for tablets, dragées and hard gelatine capsules.

Suitable excipients for soft gelatine capsules are e.g. vegetable oils,waxes, fats, semi-solid and liquid polyols etc.

Suitable excipients for the manufacture of solutions and syrups are e.g.water, polyols, saccharose, invert sugar, glucose etc.

Suitable excipients for injection solutions are e.g. water, alcohols,polyols, glycerol, vegetable oils etc.

Suitable excipients for suppositories are e.g. natural or hardened oils,waxes, fats, semi-liquid or liquid polyols etc.

Moreover, the pharmaceutical preparations can contain preservatives,solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners,colorants, flavorants, salts for varying the osmotic pressure, buffers,masking agents or antioxidants. They can also contain still othertherapeutically valuable substances.

The dosage can vary within wide limits and will, of course, be fitted tothe individual requirements in each particular case. In general, in thecase of oral administration a daily dosage of about 10 to 1000 mg perperson of a compound of general formula I should be appropriate,although the above upper limit can also be exceeded when necessary.

Example A

Tablets of the following composition are manufactured in the usualmanner:

mg/tablet Active substance 5 Lactose 45 Corn starch 15 Microcrystallinecellulose 34 Magnesium stearate 1 Tablet weight 100

Example B

Capsules of the following composition are manufactured:

mg/capsule Active substance 10 Lactose 155 Corn starch 30 Talc 5 Capsulefill weight 200

The active substance, lactose and corn starch are firstly mixed in amixer and then in a comminuting machine. The mixture is returned to themixer, the talc is added thereto and mixed thoroughly. The mixture isfilled by machine into hard gelantine capsules.

Example C

Suppositories of the following composition are manufactured:

mg/supp. Active substance 15 Suppository mass 1285 Total 1300

The suppository mass is melted in a glass or steel vessel, mixedthoroughly and cooled to 45° C. Thereupon, the finely powdered activesubstance is added thereto and stirred until it has dispersedcompletely. The mixture is poured into suppository moulds of suitablesize, left to cool, the suppositories are then removed from the mouldsand packed individually in wax paper or metal foil.

1. A compound of formula I

wherein R¹ is hydrogen, halogen, cyano, lower alkyl or lower alkylsubstituted by halogen; n is 1, 2 or 3, wherein when n is 2 or 3, eachR¹ is the same or different; R² is C₂₋₇-alkyl or C₃₋₆-cycloalkyl; R³ isthe group

wherein X is CH or N; R⁵ is hydrogen, —C(O)-lower alkyl, —C(O)O-loweralkyl, S(O)₂-lower alkyl, —C(O)CH₂O-lower alkyl, —C(O)—CH₂—CN, or is—C(O)-cycloalkyl, cycloalkyl, or —CH₂-cycloalkyl, wherein the cycloalkylgroups are optionally substituted by lower alkyl, —CH₂—O-lower alkyl,lower alkoxy, CF₃, halogen or cyano, or is —C(O)-heterocycloalkyl,heterocycloalkyl, —C(O)-heteroaryl, heteroaryl, —C(O)-aryl, or aryl,which heterocycloalkyl, heteroaryl or aryl groups are optionallysubstituted by halogen, lower alkyl, ═O, lower alkoxy, lower alkylsubstituted by halogen, lower alkyl substituted by hydroxy,—C(O)—CH₂—N(di-lower alkyl), C(O)NH-lower alkyl, C(O)NH₂, —O—C(O)-loweralkyl, C(O)-lower alkyl, S(O)₂-lower alkyl or cyano; R⁴ is aryl, whichis optionally substituted by halogen, hydroxy, lower alkyl, lower alkylsubstituted by halogen, S(O)₂-lower alkyl, cyano or by lower alkoxy; ora pharmaceutically active salt thereof.
 2. The compound of claim 1,wherein R⁴ is aryl substituted by halogen.
 3. The compound of claim 2,wherein aryl is phenyl.
 4. The compound of claim 1, having formula Ia

wherein R¹ is halogen; n is 1, 2 or 3, wherein when n is 2 or 3, eachhalogen is the same or different; R² is C₂₋₇-alkyl or C₃₋₆-cycloalkyl;R³ is the group

wherein R⁵ is hydrogen, —C(O)-lower alkyl, —C(O)O-lower alkyl,S(O)₂-lower alkyl, —C(O)—CH₂—CN, or is —C(O)-cycloalkyl, wherein thecycloalkyl groups are optionally substituted by lower alkyl,—CH₂—O-lower alkyl, lower alkoxy, CF₃, halogen or cyano, or is—C(O)-heterocycloalkyl, —C(O)-heteroaryl, heteroaryl, or —C(O)-aryl,which heterocycloalkyl, heteroaryl or aryl groups are optionallysubstituted by halogen, lower alkyl, ═O, lower alkyl substituted byhalogen, lower alkyl substituted by hydroxy, —C(O)—CH₂—N(di-loweralkyl), C(O)NH₂, —O—C(O)-lower alkyl, C(O)-lower alkyl, S(O)₂-loweralkyl or cyano; R⁴ is aryl, which is optionally substituted by halogen,or a pharmaceutically active salt thereof.
 5. The compound of claim 1,selected from the group consisting ofrac-{(3S,4R)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;rac-{(3S,4R)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-isopropyl-carbamicacid 4-fluoro-phenyl ester;rac-{(3S,4R)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-isobutyl-carbamicacid 4-fluoro-phenyl ester;rac-{(3S,4R)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-cyclopropyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3R,4S)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3R,4S)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3R,4S)-4-(4-Chloro-phenyl)-1-(4′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3R,4S)-4-(4-Chloro-phenyl)-1-(5′-methanesulfonyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrazin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester; and{(3R,4S)-4-(4-Chloro-phenyl)-1-[1-(6-cyano-pyridazin-3-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester.
 6. The compound of claim 1, selected fromthe group consisting of{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrimidin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-4-(4-Chloro-phenyl)-1-(4′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-methanesulfonyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrazin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(6-cyano-pyridazin-3-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3R,4S)-4-(4-Chloro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3R,4S)-4-(4-Chloro-phenyl)-1-(5′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-isopropyl-carbamicacid 4-fluoro-phenyl ester; and[(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-isopropyl-carbamicacid 4-fluoro-phenyl ester.
 7. The compound of claim 1, selected fromthe group consisting of[(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-isopropyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(6-cyano-pyridazin-3-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-isopropyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrazin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-isopropyl-carbamicacid 4-fluoro-phenyl ester;[(3R,4S)-4-(4-Chloro-phenyl)-1-(5′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-isopropyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-cyclopropyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-cyclopropyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-cyclopropyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(6-cyano-pyridazin-3-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-cyclopropyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(5-cyano-pyrazin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-cyclopropyl-carbamicacid 4-fluoro-phenyl ester;[(3R,4S)-4-(4-Chloro-phenyl)-1-(5′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-cyclopropyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester; and[(3S,4R)-1-(5′-Chloro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester.
 8. The compound of claim 1, selected fromthe group consisting ofEthyl-[(3S,4R)-4-(4-fluoro-phenyl)-1-(5′-methanesulfonyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;4-{(3R,4S)-3-(4-Chloro-3-fluoro-phenyl)-4-[ethyl-(4-fluoro-phenoxycarbonyl)-amino]-pyrrolidine-1-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester;[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(5′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(5′-chloro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(6′-cyano-3,4,5,6-tetrahydro-2H-[1,3′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(4′-cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(5′-fluoro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(5′-methyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester; and[(3S,4R)-1-(5′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester.
 9. The compound of claim 1, selected fromthe group consisting of[(3S,4R)-1-(5′-Chloro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-4-(3,4-Difluoro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-1-(6′-Cyano-3,4,5,6-tetrahydro-2H-[1,3′]bipyridinyl-4-carbonyl)-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(3,4-Difluoro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-1-(4′-Cyano-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-4-(3,4-Difluoro-phenyl)-1-(5′-fluoro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-4-(3,4-Difluoro-phenyl)-1-(5′-methyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(6-cyano-pyridazin-3-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-1-[1-(6-Cyano-pyridazin-3-yl)-piperidine-4-carbonyl]-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester; and[(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester.
 10. The compound of claim 1, selected fromthe group consisting of{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(5-cyano-pyrazin-2-yl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-1-[1-(5-Cyano-pyrazin-2-yl)-piperidine-4-carbonyl]-4-(3,4-difluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(5′-methanesulfonyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-4-(3,4-Difluoro-phenyl)-1-(5′-methanesulfonyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(3-methyl-oxetane-3-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(3,3-difluoro-cyclobutanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(1-cyclobutanecarbonyl-piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(1-trifluoromethyl-cyclobutanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(3-fluoro-cyclobutanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(2,2-difluoro-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(1-trifluoromethyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester; and{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(1-cyano-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester.
 11. The compound of claim 1, selected fromthe group consisting of{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(2,2-dimethyl-tetrahydro-pyran-4-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(5-trifluoromethyl-pyridine-2-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(5-fluoro-pyridine-2-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(4-cyano-benzoyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(4-fluoro-benzoyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(5-trifluoromethyl-pyrazine-2-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[1-(6-cyano-pyridine-3-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-1-(1-Acetyl-piperidine-4-carbonyl)-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(1-methanesulfonyl-piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-1-(1-Acetyl-piperidine-4-carbonyl)-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-[5′-(1-hydroxy-1-methyl-ethyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester; and{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(3-methyl-oxetane-3-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 2-fluoro-phenyl ester.
 12. The compound of claim 1, selected fromthe group consisting of{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(1-cyano-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 2-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(5-trifluoromethyl-pyridine-2-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 2-fluoro-phenyl ester;[(3S,4R)-4-(4-Chloro-phenyl)-1-(1-cyclobutanecarbonyl-piperidine-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(3-methyl-oxetane-3-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(3-fluoro-cyclobutanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(3,3-difluoro-cyclobutanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(3-methoxy-cyclobutanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(1-trifluoromethyl-cyclobutanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(2-cyano-acetyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(1-cyano-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(1-trifluoromethyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(2,2-difluoro-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester; and{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(tetrahydro-pyran-4-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester.
 13. The compound of claim 1, selected fromthe group consisting of{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(2,2-dimethyl-tetrahydro-pyran-4-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(1-methoxymethyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(2,2-dimethyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(5-trifluoromethyl-pyridine-2-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(5-fluoro-pyridine-2-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(6-oxo-piperidine-3-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-(1-isopropyl-6-oxo-piperidine-3-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-4-(4-Chloro-3-fluoro-phenyl)-1-(1-isopropyl-6-oxo-piperidine-3-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(3,4-Difluoro-phenyl)-1-[1-((S)-4-oxo-azetidine-2-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(3,4-Difluoro-phenyl)-1-[1-(6-oxo-piperidine-3-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-phenyl)-1-[5′-(1-hydroxy-ethyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-1-(5′-Carbamoyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester; and[(3S,4R)-4-(4-Chloro-phenyl)-1-(5′-chloro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester.
 14. The compound of claim 1, selected fromthe group consisting of[(3S,4R)-1-(5′-Carbamoyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-4-(3,4-Dichloro-phenyl)-1-(5′-fluoro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-1-(5′-Chloro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-4-(3,4-Dichloro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-1-(5′-Carbamoyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-4-(3-Chloro-4-fluoro-phenyl)-1-(5′-fluoro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-4-(3-Chloro-4-fluoro-phenyl)-1-(5′-chloro-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-4-(3-Chloro-4-fluoro-phenyl)-1-(5′-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-1-(5′-Acetyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl)-4-(3-chloro-4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester;{(3S,4R)-4-(4-Chloro-phenyl)-1-[1-((S)-4-oxo-azetidine-2-carbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl}-ethyl-carbamicacid 4-fluoro-phenyl ester;[(3S,4R)-1-[5′-(2-Diethylamino-acetyl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4-carbonyl]-4-(4-fluoro-phenyl)-pyrrolidin-3-yl]-ethyl-carbamicacid 4-fluoro-phenyl ester, and acetic acid4-{(3R,4S)-3-(4-chloro-phenyl)-4-[ethyl-(4-fluoro-phenoxycarbonyl)-amino]-pyrrolidine-1-carbonyl}-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-5′-ylester.
 15. A pharmaceutical composition comprising a therapeuticallyeffective amount of a compound of formula I

wherein R¹ is hydrogen, halogen, cyano, lower alkyl or lower alkylsubstituted by halogen; n is 1, 2 or 3, wherein when n is 2 or 3, eachR¹ is the same or different; R² is C₂₋₇-alkyl or C₃₋₆-cycloalkyl; R³ isthe group

wherein X is CH or N; R⁵ is hydrogen, —C(O)-lower alkyl, —C(O)O-loweralkyl, S(O)₂-lower alkyl, —C(O)CH₂O-lower alkyl, —C(O)—CH₂—CN, or is—C(O)-cycloalkyl, cycloalkyl, or —CH₂-cycloalkyl, wherein the cycloalkylgroups are optionally substituted by lower alkyl, —CH₂—O-lower alkyl,lower alkoxy, CF₃, halogen or cyano, or is —C(O)-heterocycloalkyl,heterocycloalkyl, —C(O)-heteroaryl, heteroaryl, —C(O)-aryl, or aryl,which heterocycloalkyl, heteroaryl or aryl groups are optionallysubstituted by halogen, lower alkyl, ═O, lower alkoxy, lower alkylsubstituted by halogen, lower alkyl substituted by hydroxy,—C(O)—CH₂—N(di-lower alkyl), C(O)NH-lower alkyl, C(O)NH₂, —O—C(O)-loweralkyl, C(O)-lower alkyl, S(O)₂-lower alkyl or cyano; R⁴ is aryl, whichis optionally substituted by halogen, hydroxy, lower alkyl, lower alkylsubstituted by halogen, S(O)₂-lower alkyl, cyano or by lower alkoxy; ora pharmaceutically active salt thereof and a pharmaceutically acceptablecarrier.